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ABSTRACT 
This thesis aimed to identify factors that can improve survival and reduce persisting 
symptoms among surgically treated oesophageal cancer patients. In Sweden there 
are approximately 450 new cases of oesophageal cancer and 200 new cases of 
gastric cardia cancer diagnosed every year. Surgical tumour resection is the 
mainstay of curatively intended treatment for oesophageal cancer, often preceded 
by neoadjuvant chemo- or chemoradiotherapy. Despite improvements in treatment, 
the prognosis of patients with oesophageal cancer remains poor, and even after 
successful tumour resection most patients suffer from residual symptoms.   
The included studies are based on two population-based, nationwide Swedish 
cohorts (Studies I-IV) and one Dutch (Study V), hospital-based cohort. Studies I-II 
were based on a retrospective cohort of patients operated on between 1987-2010 
and, Studies III-IV were based on a prospective cohort of patients who underwent 
surgery between 2001-2005. In Study V we used a prospective cohort of patients 
operated on between 1991-2010. Multivariable Cox regression was used to 
calculate hazard ratios (HR) with 95% confidence intervals (CI), adjusted for 
potential confounding factors.  
Study I: Among 1044 patients the number of resected lymph nodes did not 
influence survival (HR 1.00, 95% CI 0.99-1.01). Study II: Among 1822 patients, the 
200 (11%) patients who underwent reoperation had an increased risk of mortality 
(HR 1.27, 95% CI 1.05-1.53). Study III: Among 304 included patients, a cervical 
anastomosis (OR 0.86, 95% CI 0.33-2.23), creation of a fundoplication (OR 0.86, 
95% CI 0.39-1.90) or performance of a pyloric drainage procedure (OR 1.49, 95% 
CI 0.86-2.58) did not influence patients’ experience of reflux 6 months after 
oesophagectomy. Study IV: Among 277 patients followed up 6 months after 
surgery, those who suffered from an intrathoracic anastomotic leak were at 
increased risk of difficulties with eating (OR 4.05, 95% CI 1.47-11.16) and 
odynophagia OR 2.59, 95% CI 1.15-5.82), but not reflux or dysphagia. Study V: 
Among 922 patients, the 155 patients who had >10% preoperative weight loss, 
experienced an increased 5-year mortality (HR 1.34, 95% CI 1.02-1.74), but no 
increased risk of non- surgical or surgical complications. 
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3 INTRODUCTION  
Oesophageal cancer is a rather uncommon type of cancer in the Western 
world, however it is the eight most common cancer and sixth leading cause of 
cancer death worldwide.1  In Sweden approximately 450 patients are 
diagnosed with oesophageal cancer every year.2 
Due to a late and subtle clinical presentation oesophageal cancer carries a 
poor prognosis, with a 5-year survival of approximately 10% in all patients and 
30% among curatively treated patients in population-based studies.3  
Surgical tumour resection is the most well-established curatively intended 
treatment. The introduction of neoadjuvant chemotherapy or 
chemoradiotherapy has improved the long-term survival somewhat, and has 
become the routine treatment for most resectable cancers, except for very early 
tumours, in many countries.4, 5 
Oesophageal cancer resection entails an extensive surgery with a high risk of 
postoperative complications, including mortality and morbidity. Postoperative 
mortality has decreased to less than 5% in recent years,6 but oesophageal 
resection still carries a substantial risk for postoperative complications, some of 
which require reoperation.7-9 Furthermore, oesophagectomy introduces a wide 
range of physical disturbances of the alimentary tract,10 and consequently 
patients often suffer from persisting symptoms long after the operation.11-13  
Earlier studies have shown that oesophageal cancer resection has a long-
standing negative effect on health-related quality of life (HRQOL).13-16 The  
wellbeing of a patients is closely associated with their physical symptoms,17, 18 
therefore it is important to refine the surgical technique to prevent undesirable 
symptoms. 
This thesis is based on five studies in which from different angles we aim to 
identify factors that can improve survival and reduce persisting symptoms 
among surgically treated oesophageal cancer patients. 
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4 BACKGROUND 
4.1  THE OESOPHAGUS 
Surgical anatomy  
The oesophagus, also known as the “gullet” is a flattened, muscular tube that 
connects the pharynx to the stomach. The length from the upper- to the lower 
oesophageal sphincter is 18-26 cm. The oesophagus begins approximately 18 
cm from the incisors at the pharyngoesophageal junction. It descends anteriorly 
to the vertebral column into the thoracic cavity, passes through the posterior 
mediastinum and enters the abdominal cavity through the hiatus in the 
diaphragm. There it extends through the gastroesophageal junction to 
terminate in the cardiac orifice of the stomach. 
The oesophagus has three distinct anatomical regions: 1) the cervical 
oesophagus, extending from the pharyngoesophageal junction (vertebrae C5-
C6) to the suprasternal notch (vertebrae T1), 2) the thoracic oesophagus, 
extending from the suprasternal notch (vertebrae T1) to the diaphragmatic 
hiatus (vertebrae T10), and 3) the abdominal oesophagus that extends from the 
diaphragmatic hiatus (vertebrae T10) to the orifice of the cardia of the stomach.  
The oesophagus lies in close proximity to several delicate anatomical 
structures, which has important clinical implications. At the cervical level the 
oesophagus remains in close posterior relation to the trachea, and anterior 
relation to the vertebral column. In the thoracic cavity the oesophagus passes 
posterior to the trachea, tracheal bifurcation and, due to a slight left deviation, it 
lays in close proximity to the left main stem bronchus and the aortic arch. The 
lower part of the thoracic oesophagus lies close to the left atrium.  
The oesophagus consists of several muscular layers. The internal layer 
consists of longitudinal fibres and the external layer of circular fibres. The 
circular layer provides sequential peristalsis, which facilitates transportation of 
food towards the stomach. Upper and lower sphincters prevent regurgitation of 
food from the stomach.  
The vascularisation of the oesophagus is segmental and consists mainly of 
branches of arteries supplying other organs. The cervical oesophagus is 
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supplied with blood through branches of the left and right, superior and inferior 
thyroid arteries. Paired oesophageal branches of the bronchial artery and 
unpaired branches that arise directly from the anterior wall of the thoracic aorta 
supply the thoracic oesophagus. The abdominal segment of the oesophagus is 
provided with blood via the left phrenic artery, a branch of the left gastric artery 
and with the fundal arteries derived from the splenic artery.19-21 (Figure 1) 
 
The venous draining system of the oesophagus consists of two distinct 
systems. The intrinsic system, located in the submucosa, is a parallel network 
of small draining veins following the entire length of the oesophagus and 
ultimately drains in the portal vein system. It forms a connection between the 
portal vein system and the vena cava. The extrinsic venous system, like the 
arterial vascularisation, is segmental. The blood from the upper oesophagus 
drains in the azygos and the hemiazygos veins, the blood from the mid and 
lower oesophagus drains into the left gastric or splenic vein and they drain into 
the portal vein system. 19,20 (Figure 2) 
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Figure 1. Regional anatomy of the oesophagus and its surrounding structures, 
arterial blood supply 
Courtesy of Fleur van der Schaaf 
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Figure 2. Regional anatomy of the oesophagus and surrounding structures: 
venous drainage 
Courtesy of Fleur van der Schaaf 
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The lymphatic drainage system of the oesophagus consists of lymphatic 
vessels and lymph nodes. The lymphatic vessels originate in the oesophageal 
tissue as a network of endothelial channels. Drainage of lymphatic fluid is 
segmental and differs in various anatomical regions of the oesophagus. 
Lymphatic fluid of the upper part of the oesophagus drains into the deep 
cervical lymph nodes and then into the thoracic duct. The lymphatic fluid of the 
middle segment drains into the superior and inferior mediastinal lymph nodes. 
The lower third drains into the lymphatic vessels that follow the left gastric 
artery and ultimately the gastric and celiac lymph nodes. The pattern of lymph 
flow can help predict potential tumour invasions and spreading patterns.19 
(Figure 3) 
 
Similar to other internal organs, the oesophagus receives dual motor and 
sensory innervation via the sympathetic and parasympathetic division of the 
autonomic nervous system. The upper segment of the oesophagus is 
innervated by the glossopharyngeal nerve and the full length it is supplied by 
branches of the vagal nerve.20 Additionally, it has its own intrinsic neural system 
composed of flat nerve networks in the muscular layers that form the myenteric 
and submucosal plexus. The ganglia between the longitudinal and circular 
layers form the Auerbach’s plexus ganglia that lie in the submucosa form the 
Meissners plexus.19,21  
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Figure 3. Regional anatomy of the oesophagus and its surrounding structures, 
lymphatic drainage 
Courtesy of Fleur van der Schaaf 
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Histology 
Microscopically, the oesophageal wall, like the rest of the alimentary tract, 
consists of four layers: the internal mucosa, submucosa, muscularis propria 
and advertitia. A non-keratinised squamous epithelium lines the entire length of 
the lumen of the oesophagus, however, at the gastroesophageal junction it may 
coexist with a gastric type columnar epithelium.19-22 Unlike the rest of the 
gastrointestinal tract, the oesophagus has no serosa,19, 23 which means that 
oesophageal cancer tends to spread more easily and surgical anastomoses of 
the oesophagus might be weaker than those of other organs.23 
 
4.2  OESOPHAGEAL CANCER  
Epidemiology 
The two main histological types of oesophageal cancer, squamous cell 
carcinoma and adenocarcinoma, have a similarly poor prognosis but have 
otherwise distinct pathological features and epidemiological patterns. A 
characteristic of oesophageal cancer is the marked variation by geographical 
area, gender and ethnicity.24  While the incidence of oesophageal squamous 
cell carcinoma is decreasing, the incidence of oesophageal adenocarcinoma is 
increasing worldwide.25-28 In Europe alone nearly 46,000 patients were 
diagnosed with oesophageal cancer in 2012, and 39,000 patients died of the 
disease in the same year.28 The lifetime risk of developing oesophageal 
carcinoma is 0.8% for men and 0.3% for women. The risk increases with age, 
and the mean age at diagnosis is 67 years.29  
Variation in incidence of oesophageal cancer in different geographical areas is 
striking.  In the so called ‘oesophageal cancer belt’, which encompasses 
Turkey, North-Eastern Iran, Kazakhstan, and Northern and Central China the 
incidence of squamous cell carcinoma is as high as 100 per 100,000 people 
yearly.30, 31 The UK has the highest overall incidence of oesophageal 
adenocarcinoma for reasons yet unknown.3, 26 Squamous cell carcinoma is still 
the most common type of oesophageal cancer worldwide. However, between 
1975 and 2004 the incidence of adenocarcinoma among white men in the USA 
increased by 463%, leading to an overall incidence rate of oesophageal cancer 
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among white men of 8.34 per 100,000 patient years. The same trends are seen 
in the UK, other Western European countries and Australia.3, 32, 33 
There is a striking male to female ratio difference in oesophageal 
adenocarcimona,17, 18 which differs across geographical areas. In high-risk 
areas the differences seem to be smaller than in low risk areas where the ratio 
is as high as 9:1.3, 32, 34, 35 
 
Pathology 
Squamous cell carcinoma and adenocarcinoma have distinct pathological 
pathways and risk factors.  
The main risk factors for oesophageal adenocarcinoma are gastro-
oesophageal reflux,33, 36-40 Barrett’s oesophagus3, 29, 41-43 and obesity.37, 44-46 
Patients reporting symptomatic reflux at least once a week have an almost 
eight times as high risk of developing adenocarcinoma than a control group. 
Patients reporting troublesome reflux during the night are at even greater risk of 
developing adenocarcinoma.38 Barrett’s oesophagus is another major risk 
factor for oesophageal adenocarcinoma.29 It is defined by the metaplastic 
transformation of the normal squamous cell epithelium lining the oesophagus, 
to an intestinal type columnar epithelium,42, 43 as was first described in 1950 by 
Norman Barrett.47, 48 The transformation from the metaplastic Barrett’s 
oesophagus to oesophageal adenocarcinoma is a multi-step process. It 
includes transformation from metaplasia or non-dysplastic disease to low-grade 
dysplasia, then to high-grade dysplasia and then to adenocarcinoma.42 Barrett’s 
oesophagus can be considered an acquired pre-malignant disease. 
Pathogenesis of the development of the pre-malignant stage to 
adenocarcinoma is still largely unknown. Barrett’s oesophagus is strongly 
correlated with gastro-oesophageal reflux disease.29, 41-43, 49 The risk of 
developing an oesophageal adenocarcinoma in a Barrett’s oesophagus is up to 
6 to 7 per 100,000 patient years,43 although recent studies show a lower risk.49  
Central obesity, more than a high BMI alone, seems to play an independent 
role in the development of both Barrett’s oesophagus and adenocarcinoma.50, 51 
People with central obesity have a higher level of insulin-like growth factor, 
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which stimulates cell proliferation, inhibits apoptosis and determines cell 
differentiation.29, 51, 52 Additionally, obese people have a higher serum level of 
leptin, a hormone secreted by visceral fat that possibly promotes 
carcinogenesis. 29, 52-54 
Tobacco smoking is a modest risk factor for adenocarcinoma, though alcohol 
consumption does not seem to be a risk factor.39, 46, 55 It has been suggested 
that infection with Helicobacter pylori bacteria has a protective effect against 
adenocarcinoma, possibly by a mechanism including gastric atrophy and 
reduced acid secretion.56-58 
The principal risk factors for the development of squamous cell carcinoma are 
excessive tobacco smoking and alcohol intake.33, 37, 59-62 A clear synergistic 
effect of combined tobacco smoking and alcohol consumption has been seen.59 
Other weaker risk factors that have been suggested include ingestion of hot 
beverages, consumption of fungus food, dietary deficiencies and infection with 
human papilloma virus (HPV).63, 64 
 
Diagnosis and staging 
Diagnosis and staging of oesophageal cancer is a multidisciplinary process.65 
Oesophageal cancer patients most often present with progressive dysphagia 
accompanied by weight loss and fatigue.3, 33, 37 Less often oesophageal cancer 
presents as hoarseness, dyspnoea, coughing or pain, which all typically reflect 
an advanced disease.3 On physical examination of the patient there are often 
no clinical signs of disease. Due to the elasticity of the oesophageal wall, 
symptoms of dysphagia might not occur until the tumour is in an advanced 
stage and obstructs the larger part of the lumen of the oesophagus. Due to this 
late presentation of oesophageal cancer, over 50% of patients have an 
unresectable disease by time of diagnosis.37  
Oesophageal cancer is diagnosed by upper gastrointestinal endoscopy.3, 33, 37, 
65, 66 During this procedure biopsies are taken to histologically confirm the 
diagnosis which is most accurate when at least 6 biopsy samples are taken.66 
For further staging, endoscopic ultrasound (EUS) is performed to assess the 
depth of the tumour invasion and thus define the T-stage of the tumour.66, 67 It 
also aids in detecting suspected locoregional lymph nodes through EUS-guided 
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fine needle aspiration.67, 68 A computer tomography (CT) of the abdomen and 
thorax is primarily used for the detection of any distant metastasis.66, 68, 69 
Positron emission tomography (PET) scans have also been shown to be 
valuable in this process.33, 37, 66, 69, 70 The staging classification most often used 
is the tumour nodal metastasis (TNM) system developed by Pierre Denoix in 
the 1940’s,33, 71 and maintained by the International Union Against Cancer 
(UICC) and the American Joint Committee on Cancer (AJCC). The TNM 
system takes into account the depth of the tumour invasion (T), the involvement 
of lymph nodes (N), and presence of distant metastatic disease (M).33 Accurate 
staging is of great importance since it dictates the prognosis and the choice of 
treatment.3, 66, 67, 72  
 
Treatment 
Surgical treatment 
 
“The aims of radical cancer surgery are: (a) to cure disease; while (b) rendering 
the patient’s life useful and enjoyable, or at least bearable”- Ivor Lewis, 1946. 
 
Surgery of the oesophagus has been historically problematic due to the 
inaccessibility of the organ, lack of a serous coating and its proximity to 
structures where infection is especially dangerous and rapid.73,74 This has 
considerably delayed the development of oesophageal cancer surgery in the 
past.75,76  There are only a few reports on surgery of the oesophagus from 
ancient and classic periods. The first written observations of oesophageal 
anatomy and pathology stem from ancient Egypt, written on the “Smith Surgical 
Papyrus” found in 1862 by archaeologist Edwin Smith.77 Many surgeons have 
had reservations about operating on the oesophagus in the past due to its tricky 
anatomical location. In 1877 a surgeon named Czerny performed the first 
successful resection of the cervical oesophagus.76 Czerny was a pupil of 
Theodore Billroth, “the founding father of abdominal surgery”.78 Czerny 
successfully removed an annular tumour, just below the pharynx, through a 
local excision in the neck. The remnant pieces of the oesophagus were closed 
blindly and a cervical oesophagostomy was created for feeding purposes.76   
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General developments in medicine facilitated the development of oesophageal 
surgery, which resulted in the first successful transpleural oesophagectomy, 
performed by Torek in 1913.74  He removed a mid-oesophageal tumour by an 
incision through the seventh intercostal space and the remnant upper stump of 
the oesophagus was tunnelled under the skin to make an oesophagostomy on 
the anterior chest wall. Continuity of the oesophagus was never restored during 
those years. 
With the use of the Kocher manoeuvre to mobilise the duodenum, it was 
discovered in 1947 that the stomach could be placed in the thoracic cavity, 
facilitating oesophagogastrostomy and restoration of continuity of the 
gastrointestinal tract. The first successful resection with direct reconstruction, 
with oesophagogastric anastomosis, was described by Oshawa in Japan in 
1933.76 The British surgeon Ivor Lewis developed a method for resection of the 
middle third of the oesophagus, first described in the literature in 1946.73 His 
two-stage right-sided thoracotomy technique with laparotomy to mobilise the 
oesophagus and stomach is still often used for tumours of the oesophagus or 
gastroesophageal junction.73, 79 Historically, this procedure was performed with 
a week in between the thoracotomy and the laparotomy.80 
The transhiatal oesophagectomy has been performed in many different ways 
by surgeons in the past,81 but was brought attention again in 1978 by the 
American surgeons named Orringer and Sloan.82, 83 The aim of the 
performance of a transhiatal, rather than a transthoracic oesophagectomy, was 
the avoidance of a combined thoracic and abdominal incision in debilitated 
patients, and avoidance of an intrathoracic anastomosis with the potential to 
leak and cause life-threatening mediastinitis.84 
Despite the introduction of multimodal strategies in the treatment of 
oesophageal cancer, surgical tumour resection is still the cornerstone of 
oesophageal cancer treatment. There are a large number of surgical 
techniques currently used to remove the oesophagus of which the most used, 
transthoracic and transhiatal oesophagectomy will be described below.  
 
Transthoracic oesophagectomy 
The classic transthoracic Ivor Lewis oesophagectomy is a combined approach: 
a laparotomy and right-sided thoracotomy. The abdominal procedure often 
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starts with a midline epigastric incision extending into the paraumbilical region. 
(Figure 4) This allows meticulous exploration of the abdomen to assess tumour 
extent and spread; in this stage the stomach is mobilised. The left gastric artery 
and vein are divided and the short gastric vessels are divided. The right gastric 
artery and mainly the gastro-epiploic arch are now the only contributors of 
blood supply to the gastric conduit. Lymphatic tissue along the celiac axis is 
often resected during the abdominal part of the oesophagectomy. A Kocher 
manoeuvre is sometimes performed to mobilise the duodenum, to facilitate the 
gastric pull-up and the stomach is used to create an oesophageal substitute, 
usually by making it into a gastric tube. 
The thoracic part of the operation begins with a right-sided posterolateral 
thoracic incision, (Figure 4) which allows exposure of the oesophagus without 
interfering with the aortic arch. The oesophagus is mobilised while the azygos 
vein is divided. After this the oesophagus is dissected while mediastinal, 
perioesophageal and subcarinal lymph nodes are often removed. The 
oesophageal substitute is brought into the chest and connected to the remnant 
proximal oesophagus, often with an end-to-side anastomosis in the upper 
chest. (Figure 5) 
A variation on the Ivor Lewis oesophagectomy is the 3-incision, or McKeown, 
oesophagectomy, where an additional right-sided cervical incision is made and 
the anastomosis is created in the neck instead of the upper chest. This 
technique is preferred for patients with tumours above the carina. The cervical 
incision allows wider resection margins for tumours of the upper third of the 
oesophagus.85 This procedure usually starts with a thoracotomy rather than 
with a laparotomy to allow assessment of the thoracic resectability of the 
tumour. After that, the abdominal part with the gastric mobilisation is similar to 
the Ivor Lewis oesophagectomy. As a last step, a right cervical incision is made 
along the anterior border of the sternocleidomastoid muscle, to mobilise and 
resect the cervical part of the oesophagus. The resected oesophagus is 
removed through the abdominal incision and the oesophageal substitute is 
pulled up to the neck through the posterior mediastinum. Finally, a cervical end-
to-end or end-to-side anastomosis is created.19, 79 
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Figure 4. Schematic overview of the incisions (dotted lines) during 
transthoracic oesophagectomy and transhiatal oesophagectomy 
Courtesy of Fleur van der Schaaf 
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Transhiatal oesophagectomy 
During transhiatal oesophagectomy, the resection of the oesophagus is 
accomplished through incisions in the abdomen and in the neck. (Figure 4) The 
distal part of the oesophagus and the most proximal part are dissected under 
direct vision, but a part of the thoracic oesophagus is blindly mobilised. The 
operation begins in the same fashion as the transthoracic oesophagectomy, 
with an incision and exploration of the abdomen, exposure of the diaphragmatic 
hiatus, resection of the lymph nodes along the celiac axis and mobilisation of 
the stomach. The gastroepiploic arch is preserved while the left gastric artery 
and vein are divided. To widen the hiatus and obtain better visibility and 
accessibility, the diaphragm is usually incised anteriorly. The blunt dissection of 
the thoracic oesophagus is performed posteriorly along the aorta and spine 
followed by anterior dissection along the trachea and pericardium. The lateral 
aspects of the oesophagus are more complicated to dissect bluntly as they 
include small vessels and branches of the vagal nerve. A left cervical incision is 
made and dissection of the cervical oesophagus is performed. (Figure 4) 
Mobilisation of the upper thoracic oesophagus is performed by manual 
dissection by entering the mediastinum through the cervical incision and the 
lower oesophagus is mobilised from the abdominal side through the incision in 
the hiatus. The oesophagus is divided in the neck and gastric conduit or colon 
is brought to the neck after resection of the specimen containing the tumour. A 
side-to-side or end-to-side cervical anastomosis is created and the hiatal 
opening in the diaphragm is sometimes narrowed.19, 79, 80
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Technical considerations 
 
Choice of surgical approach 
The choice of surgical approach depends on several factors: the location of the 
tumour, the desired extent of lymph node resection (see section “Extent of 
lymph node dissection”) and comorbidity, the patient’s habitus and also the 
surgeon’s experience and preference.79  
The transthoracic approach seems to be more common in patients with 
oesophageal tumours, while transhiatal might be more suitable for patients with 
gastroesophageal junction tumours or cardia tumours. 86 
Some retrospective studies have shown a higher risk of pulmonary 
complications after transthoracic oesophagectomy.87 These results were 
confirmed in a recent randomised controlled trial;88 the length of intensive care 
and hospital stay were longer in the transthoracic group. However, no studies 
have been able to show a significant survival difference in favour of any one of 
the two main approaches. One randomised controlled trial (RCT) showed a 
trend towards a better 5-year survival in favour of the transthoracic group, but 
this did not reach statistical significance.89 Subgroup analyses of an updated 
version of the same RCT showed improved overall and disease free survival in 
patients with 1-8 positive lymph nodes in favour of the transthoracic approach, 
while this was not the case for patients without involved lymph nodes or those 
with more than 8 metastatic lymph nodes.89 The use of one-lung ventilation 
during transthoracic oesophagectomy could cause excessive stress on both the 
ventilated and the unventilated lung and might induce post-ventilation injuries.90 
Consequently, for patients with comorbid lung disease, a transhiatal approach 
without thoracotomy might be safer. Preoperative respiratory dysfunction has 
been associated with an increased risk of pulmonary complications.91 Since the 
risk of pulmonary complications is higher after transthoracic oesophagectomy, 
patients with preoperative pulmonary dysfunction might be better off 
undergoing a transhiatal oesophagectomy. 
 
Minimally invasive oesophagectomy  
During recent years several minimally invasive techniques have been 
developed for both transthoracic and transhiatal oesophagectomy. Surgeons 
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around the world more and more frequently use minimally invasive techniques 
and its development is ongoing.68, 86 Other techniques, such as thoracoscopic 
and laparoscopic techniques are also used to perform oesophagectomy. 
Minimally invasive oesophagectomy has been shown to decrease blood loss 
during operation, and decrease the risk of some postoperative complications.92 
However, the rate of severe complications is similar to open techniques as is 
postoperative mortality.93, 94 There is in particularly a higher risk of gastric tube 
necrosis with minimally invasive techniques that needs further investigation.68 
Oncological outcomes are still under investigation; no long-term follow-up 
studies are yet available. However, existing data indicate a similar survival after 
minimally invasive oesophagectomy and open oesophagectomy.93, 94 
If minimally invasive oesophagectomy will be the standard treatment for 
oesophageal cancer patients in the near future remains to be seen as there are 
still several safety and long-term outcome issues that remain to be investigated. 
For example, the safety of thoracoscopic-assisted resection after radiotherapy 
is under debate.94 Another problem is the learning curve;95 to date no large high 
quality studies have been performed,86 and further research is warranted before 
any recommendations can be made.  
 
Extent of the lymph node dissection 
The extent of the lymph node dissection has since long been a subject of 
debate. Nodal status is considered on of the most important prognostic factor 
after oesophageal cancer resection96 and radical lymphadenectomy might 
therefore be important to improve survival.97 The aim with a more extensive 
lymphadenectomy is improvement of the staging, the reduction of local 
recurrence and ensuring oncological completeness of the resection.96, 98 It 
should be taken into consideration, however, that a more extensive 
lymphadenectomy increases the surgical trauma and the risk of 
complications.98, 99 There is a delicate balance between optimal oncological 
treatment and the prevention of postoperative complications and early death. 
Current clinical guidelines typically recommend an extensive two-field 
lymphadenectomy, although the scientific evidence to support such a strategy 
is weak.33, 68, 86, 100  
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Multimodal treatment 
Multimodal treatment for oesophageal cancer (e.g. chemo- or 
chemoradiotherapy) combined with surgery has long been a subject of debate,5 
and local clinical policy has often dictates the treatment regimen for 
oesophageal cancer patients.  
Neoadjuvant treatment of oesophageal cancer aims to decrease the risk of 
recurrence and distant metastasis by eliminating micro metastasis and aiming 
to increase radical resectability.101 In the past, mixed results have been 
published, some studies showing a survival advantage102, 103 from neoadjuvant 
chemo or chemoradiotherapy and some studies showing no such 
advantage.101, 104, 105 However, in recent years some high quality RCTs have 
shown that there is a significant survival benefit from multimodal treatment.4, 5, 
102, 106 It remains unclear whether patients benefit most from perioperative 
chemo-107, 108 or chemoradiotherapy, however.109, 110  
 
Complications 
Despite the improvements in surgical technique, anaesthesia and postoperative 
care, oesophagectomy is still risky surgery with a reported mortality rate of 1.6-
4.0% and morbidity rate of 29-45%. 111-115 
The majority of patients develop a medical complication rather than a surgical 
technical complication.112 Pulmonary complications, in particular pneumonia, 
are the most frequently reported serious complications and one of the most 
frequent causes of postoperative death.112, 115-117 The high incidence of 
postoperative pulmonary complications is caused by the combination of the two 
stages of the traditional Ivor Lewis oesophagectomy: thoracotomy and 
laparotomy. The tumour sub-site is an important factor for the development of 
pulmonary complications, with the highest risk in upper abdominal and thoracic 
procedures.118 Other commonly reported medical complications are (often 
benign) cardiac arrhythmias, myocardial infarction, infections (urinary tract 
infections, infective diarrhoea) and neurological complications.112, 114, 115, 117 
Intrathoracic anastomotic leaks are one of the most feared and severe surgical 
complications following oesophageal resection, responsible for 25-50% of 
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postoperative deaths.112, 119-121 The reported incidence of intrathoracic 
anastomotic leaks is between 3% and 12%.119-124 The leak rate in cervical 
anastomosis is higher and can be up to 50%.121, 125 The aetiology of 
anastomotic leaks is multi-factorial, but ischemia of the oesophageal substitute 
(conduit) and surgical technical errors seem to be the most important 
predisposing factors.121, 126 Also, an important patient related factor that is 
associated with a higher risk for anastomotic leak is comorbidities that 
compromise vascularisation and blood.125, 127 The severity of the anastomotic 
leak and its consequences are largely dependent on the location of the 
anastomosis and containment by the surrounding tissue.128, 129 Leakage of 
gastro-intestinal contents into the thoracic cavity can have disastrous 
consequences, such as fulminant mediastinitis and septicaemia,122 while 
leakage in the neck are less severe from this point of view.  
Benign anastomotic strictures are common after oesophageal resection. There 
are several known risk factors for such a stricture; cervical anastomosis tends 
to cause strictures more often than intrathoracic anastomosis,130 and another 
risk factor is anastomotic leak.124, 131, 132 Anastomotic strictures might give rise 
to symptoms of dysphagia and trouble eating and can be quite debilitating for 
patients.130, 132 
 
Prognosis 
Cancer mortality in general has slowly but steadily decreased over the past 
decades, with the exception of pancreatic cancer and lung cancer in 
females.133, 134  
Despite attempts to improve the diagnostic procedure, staging and treatment, 
the prognosis for oesophageal cancer patients remains poor.3However, over 
the last five decades the prognosis has improved to some extent. A population-
based study with data from Sweden showed that 5-year survival for 
adenocarcinoma has improved from 4% in the early 1960’s to 10.5% in the late 
1990’s. For squamous cell carcinoma, the 5-year survival increased from 3.8% 
to 7% during the same period.135 Overall survival for both histological types 1, 
3, and 5 years after surgery was 61.7%, 39.9% and 30.7%, respectively, in the 
late 1990’s to the early 2000’s compared to 46.5%, 24.1% and 19.7% in the 
 30
late 1980’s.136 This improved survival compared to earlier decades could not be 
explained by differences in patient characteristics, and might be due to 
improved surgical treatment. Recent studies using mortality data from the Word 
Health Organisation (WHO) reported a continuing decline in mortality after 
oesophageal cancer diagnosis.25, 137  
There are several known prognostic factors that influence survival in patients 
who have undergone surgical tumour resection. Several studies have shown 
that increasing age is a marker of worse prognosis.135, 138, 139 Strong prognostic 
factors include tumour stage,72, 140 tumour differentiation,72, 141 lymph node 
status,142Ͳ144and surgeon and hospital volume.145-149 
 
Health-related quality of life (HRQOL) and persisting symptoms  
Health-related quality of life: The concept         
Over the last 30 years, due to tremendous improvements in treatment and 
survival for most cancers, there has been increased concern about the cancer 
patient’s wellbeing and psychosocial functioning. Quality of life has been 
referred to in many ways depending on the time and the circumstances. In the 
declaration of independence of the United States of America it is referred to as 
the “right to pursue happiness”, and during the Great Depression in the 1930’s 
it was material objects and wealth that determined quality of life. In the 1960’s 
the social aspects of health and quality of life gained more acceptance. Quality 
of life became the pursuit of individual happiness and individual growth, rather 
than possessions or accomplishments.150 However, this posed a challenge, 
since happiness and personal growth are not objective measures and it 
became difficult to reliably measure this new concept of quality of life. The idea 
emerged that quality of life was a multidimensional construct influenced by 
different aspects in a person’s life such as social, emotional, physical and 
economic wellbeing.  
Health-related quality of life has been described as encompassing those 
aspects of overall quality of life that clearly affect physical or psychological 
health. It refers to broad concepts of physical, psychological and social-
wellbeing often assed in patients with different diseases.151-153 
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Health-related quality of life in cancer patients 
Cancer has relatively recently gained the status of a manageable, chronic 
disease rather than one which is fatale. This has caused a delay in the 
development of the HRQOL constructs in these patients in the past.150 For 
many years, survival was the single endpoint in much clinical cancer 
research.154 However for patients, HRQOL is a very important outcome 
measure. Oesophageal cancer patients often suffer from severe symptoms and 
a decrease in HRQOL long after surgery.13, 155, 156 The experience of symptoms 
in long-term survivors of oesophageal cancer surgery deserves attention since 
previous research shows that the surgery substantially influences symptom 
experience negatively in the short- and longer-term.11, 156-159 Six months after 
surgery patients report a deterioration in role function, social function and 
several symptoms, including appetite loss, diarrhoea, dyspnoea, trouble eating, 
reflux, odynophagia, dry mouth, dysphagia, coughing and chest pain.156, 160 
There has been an advance in the development of HRQOL assessment tools 
and validated questionnaires that can reliably measure HRQOL are 
available.156 There are both general cancer-specific questionnaires and site-
specific questionnaires developed. HRQOL has become an accepted and 
increasingly acknowledged outcome, and is usually included in current clinical 
trials. In this thesis we chose to use the well-established cancer-specific 
questionnaire developed and validated by the European Organization for 
Research and Treatment of Cancer (EORTC), the QLQ-C30,161-163 and the 
oesophageal cancer-specific module, the QLQ-OES18.162 The QLQ-C30 is a 
cancer-specific core questionnaire that contains questions about symptoms that 
are common amongst cancer patients. The questionnaire consists of 30 
questions which create 5 functional scales (emotional, physical, cognitive, 
social and role function), 1 global quality of life scale and 3 symptom scales 
(fatigue, nausea and vomiting, and pain). It also contains 6 single items 
common amongst cancer patients (dyspnoea, sleeping disorders, loss of 
appetite, diarrhoea, constipation and financial problems). The oesophageal 
cancer-specific questionnaire, the QLQ-OES18 assesses symptoms commonly 
reported by oesophageal cancer patients. The QLQ-OES18 consists of 18 
questions which generate 4 symptom scales (dysphagia, eating difficulties, 
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reflux and odynophagia) and 6 single items (dry mouth, trouble swallowing 
saliva, choking, taste, cough and speech difficulties).  
 
Symptoms 
The concept of symptom experience has been described as “the occurrence of 
sickness or disease and the patient’s response to the symptoms”, but to date 
no clear concept has been formulated.164 Besides a reported decrease in 
general HRQOL and functioning, patients with oesophageal cancer often report 
persisting symptoms long after treatment has been completed.10, 154 In this 
thesis we chose to assess symptoms often reported by oesophageal cancer 
patients rather than general HRQOL since the selected symptoms potentially 
influence all aspects of quality of life.164 Symptoms were measured using the 
questionnaires mentioned in the section above and, hence, are subjective 
rather than objective measures.  
 
Persisting symptoms 
 
Oesophagectomy for oesophageal cancer is one of the most extensive surgical 
procedures used in humans. Besides the postoperative complications and long 
recovery, patients often suffer from persisting symptoms long after the 
operation.11-13 Oesophagectomy introduces a wide range of physical 
disturbances of the alimentary tract.10  
Gastro-oesophageal reflux of duodeno-gastric contents (reflux) is a common 
and troublesome problem whenever a gastric conduit replaces the resected 
oesophagus.10, 165, 166 Symptoms of reflux have been reported by up to 60-80% 
of patients after oesophagectomy.18, 167 Such postoperative reflux, especially 
when using a supine position, introduces a risk of aspiration pneumonia.18 After 
such surgery, reflux might present as regurgitation, aspiration (pneumonia) or 
chronic cough rather than as heartburn, which is normally a cardinal symptom 
of reflux. Reflux is caused by disruption of several natural antireflux barriers, 
e.g. the lower oesophageal sphincter, the angle of His, and the diaphragmatic 
sling, and the creation of a positive intra-abdominal pressure.18, 168 Post-
oesophagectomy reflux can have disrupting consequences; it can cause reflux 
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oesophagitis and Barrett’s oesophagus of the oesophageal remnant, and 
aspiration.169  
Some potential solutions to prevent reflux after oesophagectomy have been 
studied, but many of the results are conflicting. The role of the location of the 
anastomosis remains a subject of debate. It has been hypothesises that a 
cervical anastomosis might be less associated with reflux compared with an 
intrathoracic anastomosis, since a cervical anastomosis reduces the amount of 
stomach exposed to the positive intra-abdominal pressure.18, 170 Some studies 
hypothesised that a cervical anastomosis is more likely to cause reflux and 
some studies argue that an anastomosis below the aortic (e.g. intrathoracic) 
arch is “refluxogenic” since a larger part of the remnant oesophagus is exposed 
to positive intra-abdominal pressure.14 A suggested surgical solution is the 
creation of an “anti-reflux anastomosis” that might prevent reflux.17, 18, 166 
Whether pyloric drainage reduces the risk of reflux after oesophagectomy is a 
matter of debate. Results from previous studies are contradictory,171-174, 175 one 
study showed absence of reflux after the pyloric drainage procedure,176 while 
others have shown an increase in bile reflux after pyloric drainage 
procedures.172, 174  Proton-pump inhibitors are routinely prescribed after 
oesophagectomy and they might be the most potent solution to counteract 
postoperative reflux, however, few studies have been published on this 
subject.177  
Delayed gastric emptying is another frequently reported problem. The 
necessary bilateral vagotomy during oesophagectomy typically causes 
dysmotility of the gastric remnant and the pylorus, causing gastric outlet 
dysfunction.10, 171 These two phenomena might cause symptoms of delayed 
gastric emptying. Patients with delayed gastric emptying clinically present with 
nausea and vomiting, regurgitation, early satiety and post-prandial fullness.10, 
171 Besides troublesome symptoms, delayed gastric emptying may give rise to 
serious complications such as aspiration pneumonia, which can be fatal.178 
There is currently no clear consensus regarding the best approach to prevent 
delayed gastric emptying and the results of previous studies have been 
contradicting.167, 172, 174, 179  
Other, less frequent symptoms include dysphagia,167 fatigue, diarrhoea12, 
nausea and vomiting and loss of appetite.11, 159 
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5 AIMS OF THE STUDIES 
5.1 OVERALL AIM OF THIS THESIS:   
To identify factors that can improve survival and reduce persisting symptoms 
among surgically treated oesophageal cancer patients 
 
5.2 SPECIFIC AIMS OF THE STUDIES IN THIS THESIS WERE: 
x To assess how lymph node clearance (the number of lymph nodes 
resected, the number of metastatic lymph nodes and the lymph node 
ratio) influence survival of oesophageal cancer patients.  
x To examine the impact of reoperation within 30 days of operation, on 
long-term survival after primary oesophageal cancer surgery.  
x To clarify if an anti-reflux anastomosis, cervical anastomosis or pyloric 
drainage prevent reflux or dysphagia 6 months after oesophagectomy 
for cancer.  
x To reveal whether intrathoracic anastomotic leak influences the 
development of symptoms after oesophagectomy for cancer. 
x To investigate any influence of preoperative weight loss (>10%) on the 
postoperative course. 
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6 MATERIAL AND METHODS 
6.1 DATA SOURCES 
Studies I and II 
 “The Swedish Esophageal Cancer Surgery Study (SESS)” 
This Swedish nationwide population-based retrospective cohort included 
patients who have undergone oesophageal cancer resection with curative 
intent in the period between 1987-2010. Patients eligible for inclusion were 
identified from the Swedish Cancer Register, a nationwide register with 98% 
coverage.180, 181 Patients were identified from the Cancer Register using the 
diagnostic code for oesophageal cancer (150.0, 150.8, and 150.9) according to 
the 7th version of the International Classification of Diseases (ICD7). The 
oesophageal cancer patients who underwent tumour resection were identified 
from the Swedish Patient Registry, which has an excellent (99.6%) positive 
predictive value for oesophageal surgery.182 Additionally, relevant medical 
records containing operation notes and histopathological reports of the studied 
patients were retrieved from all hospitals in Sweden where oesophageal cancer 
surgery had been performed. All medical records were carefully reviewed 
according to a predefined study form. Data regarding lymph node resection, 
neoadjuvant therapy, as well as tumour (TNM) stage, location, (surgical) 
radicality and histology were obtained from these records. Tumour stage was 
classified according to the 6th TNM classification of the Union Internationale 
Contre le Cancer (UICC), as some information that is necessary to stage 
according to the 7th edition of the TNM classification was not available when the 
cohort was initiated in 1987. The accuracy of the histopathological review was 
assessed by two researchers who independently reviewed 100 patient records, 
showing high accuracy (>90% concordance).136 Information on patients’ 
comorbidity and hospital admittance were collected from the Swedish Patient 
Registry.182 By linking the oesophageal cancer surgery cohort to the highly 
complete and continuously updated Swedish Causes of Death Registry, data 
on death dates and causes of death were ascertained.183 The linkage of data 
from all individual cohort members between registries and medical records 
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were made possible by virtue of the Swedish 10-digit personal identity number, 
assigned to each Swedish resident upon birth or immigration.184 Patients were 
followed-up until death or the end of the study period (31st of December 2012), 
whichever occurred first. 
 
Studies III and IV 
“The Swedish Esophageal and Cardia Cancer study (SECC)” 
 
SECC is a prospective nationwide research cohort that includes 90% of all 
newly diagnosed patients with oesophageal or cardia cancer in Sweden, who 
underwent surgery between 2001 and 2005.185 The establishment of SECC 
was facilitated by an earlier established collaboration with the nationwide 
Swedish network of hospitals and physicians involved in the diagnosis and 
treatment of oesophageal cancer patients.38, 106, 114, 154 Patients in SECC were 
identified shortly after histopathological confirmation of the diagnosis, through 
collaboration with the pathology departments of the participating hospitals. A 
specialised project coordinator, who was a key contributor to the collection of 
the data and she (Eja Fridsta) received all the histopathological reports from the 
pathology departments and reminded physicians to include their oesophageal 
cancer patients in the study and send all clinically relevant information. She 
was also responsible for the assembly of all the files into the database. Before 
inclusion in the SECC study, informed consent was obtained from all patients.  
SECC contains details on tumour characteristics, surgical procedures and 
complications as well as HRQOL data. The clinical data was collected through 
medical records according to a predefined protocol, to ensure objectivity and 
uniformity. The almost complete national coverage and the detailed prospective 
data collection and objective review of each case ensured good validity. 
The data collection additionally contains HRQOL assessments at three points: 
6 months, 3 years and 5 years after surgery. Collection of 10-years post-
surgery follow-up data is ongoing. In SECC the cancer-specific HRQOL 
questionnaire, the QLQ-C30 and the oesophageal cancer-specific 
questionnaire, the QLQ-OES18, were used to assess HRQOL. The project 
coordinator contacted and reminded patients to return the questionnaires.  
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Patients were followed up, regarding survival, until 5 years after surgery or until 
death, whichever occurred first. 
 
Study V 
“The Rotterdam Oesophageal Cancer database “ 
 
The Rotterdam Oesophageal Cancer database was established in 1978 by the 
Rotterdam Oesophageal Cancer Group. Included were patients diagnosed with 
invasive squamous cell carcinoma or adenocarcinoma of the oesophagus or 
gastroesophageal junction. Patients were treated at the Erasmus MC- 
University Medical Center in Rotterdam, the Netherlands. All included patients 
had undergone surgical tumour resection, with or without preoperative 
chemotherapy or chemoradiotherapy, from May 1, 1990 to October 29, 2010. 
Up until October 29, 2010 a total of 1271 patients were included. Information on 
patient demographics, clinical and pathologic characteristics, treatment, 
surgical procedure, and postoperative course was partly prospectively and 
partly retrospectively abstracted form medical records by a data manager.  
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6.2  DESIGN AND METHODS 
Study I 
Using SESS, this study assed the influence of lymph node clearance i.e. the 
number of resected lymph nodes, number of metastatic lymph nodes and the 
ratio between metastatic and total resected lymph nodes on overall and 
disease-specific mortality. We hypothesised that a more extensive lymph node 
clearance would have a beneficial effect on the long-term survival in all T-
stages, but mainly in higher T-stages, with a more beneficial survival 
associated with more lymph nodes resected, less metastatic lymph nodes and 
a lower ratio of metastatic and total number of resected lymph nodes.  
The primary study outcome was overall all-cause mortality up to 5 years after 
surgery.  Short-term (90-day), longer-term (90 days to 5 years) and disease-
specific mortality were secondary outcomes. Short- and longer-term mortality 
were counted from the day of the operation up to 90 days after surgery, and 
from 90 days to 5 years after surgery, respectively. Patients who died within the 
first 90 days of surgery were censored from the long-term survival analyses 
because they most likely died from postoperative complications. Disease-
specific mortality was assessed from the Swedish Causes of Death Register. 
When the code for oesophageal cancer was recorded as the cause of death 
the assumption was made that the patient had died of recurrent disease. We 
were not able to distinguish between local or distant recurrence. 
 
Study II 
Using SESS cohort the influence of any reoperation within 30 days after 
oesophagectomy for cancer on long-term survival was assessed. It was 
hypothesised that reoperation would negatively influence survival even after the 
initial postoperative period. The exposure was defined as any open or minimally 
invasive reoperation within 30 days of the initial oesophageal cancer resection. 
More specifically, reoperation was categorised as: 1) explorative laparotomy, 2) 
explorative thoracotomy, 3) reoperation for bleeding, 4) reoperation for 
anastomotic insufficiency and 5) reoperation for deep infection.  
 40
The outcomes were all-cause early and late mortality. “Early postoperative 
mortality” was defined as any death occurring within 90 days of the initial 
surgery, while “late mortality” was defined as any death between 90 days and 5 
years of the primary resection.  
 
Study III 
Patients included in this study were identified from SECC and a study was 
conducted to test the hypothesis that reflux symptoms after oesophagectomy 
can be prevented surgically by creation of a cervical anastomosis, anti-reflux 
procedure around the anastomosis or a pyloric drainage procedure. The 
cervical anastomoses were conducted through a standard left-sided neck 
incision. The typical antireflux procedure was the creation of a full or partial 
wrap of the most proximal part of the gastric tube surrounding the anastomosis. 
The pyloric drainage procedure was a pyloromyotomy or a pyloroplasty. 
The primary outcome was symptoms of reflux present at 6 months after 
oesophageal resection in patients reconstructed with a gastric tube. A 
secondary outcome was symptoms of dysphagia, which e.g. a cervical 
anastomosis might cause. To address time-related changes we also aimed to 
studied symptoms of reflux and dysphagia 3 years after surgery, although the 
statistical power might be insufficient. Both outcomes were measured using the 
QLQ-OES18.162, 186 The scale assessing reflux symptoms in the QLQ-OES18 
consists of two questions: 1) During the past week have you had any acid 
indigestion or heartburn and 2) During the past week have you had trouble with 
acid or bile getting into your mouth? These questions have been found to be of 
good quality to distinguish symptoms of reflux.187 The dysphagia scale consists 
of three questions: 1) During the past week, could you eat solid foods, 2) 
During the past week could you eat liquidized or soft food, and 3) During the 
past week could you drink liquids.162 These two scales have been shown to 
have good reliability and discriminative validity.162 
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Study IV 
In this study the incidence of persisting symptoms after intrathoracic 
anastomotic leak following oesophagectomy for cancer was investigated using 
SECC.  
It was hypothesised that intrathoracic anastomotic leak would make patients 
more susceptible to certain symptoms.  
Anastomotic leak was defined as “intrathoracic anastomotic leak that was 
clinically evident and verified by radiological imaging; this included necrosis of 
the gastric conduit with clinically significant ischemia causing perforation or 
ulceration, or oesophago-tracheal fistula that was clinically evident and verified 
through radiological imaging”. The leak had to have occurred within 30 days of 
surgery. 
Five pre-defined outcome symptoms were: 1) difficulty eating, 2) odynophagia, 
3) dysphagia, 4) trouble swallowing saliva and 5) reflux. These were measured 
using the QLQ-OES18.162 The difficulty eating-scale consists of 4 questions: 
During the past week have you: 1) had trouble enjoying your meals, 2) felt full 
up too quickly, 3) had trouble with eating and 4) had trouble eating in front of 
others. The odynophagia scale consists of 3 questions: During the past week 
have you had 1) pain when you eat, 2) pain in your chest, and 3) pain in your 
stomach. The dysphagia scale consists of 3 questions: During the past week 
could you 1) swallow solid food, 2) eat liquidised food or soft food and 3) drink 
liquids. Trouble swallowing saliva is a single item in the QLQ-OES18: During 
the last week have you had trouble swallowing saliva. The reflux scale consists 
of two items: During the past week have you had 1) acid indigestion or 
heartburn and 2) trouble with acid or bile coming into your mouth. The patients 
were followed up for 6 months and 3 years after oesophageal cancer resection 
 
Study V 
To assess the influence of preoperative weight-loss on postoperative outcome, 
the comprehensive, hospital-based, Rotterdam Esophageal Cancer cohort was 
used. In this study we tested the hypotheses that oesophageal cancer patients 
with >10% preoperative weight loss would be at an increased risk of 
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postoperative complications, have a longer length of stay, and have a worse 
overall and disease-free survival. The exposure was defined as weight loss 
during the 3 months prior to diagnosis and categorised into “no or limited 
(10%)” or “severe (>10%) weight loss”. 
The patients estimated their weight 3 months prior to their first visit, which was 
considered as the baseline weight. Patients were also weighed at their first visit 
to the outpatient clinic (actual weight). Percentage of weight loss in the 3 
months prior to diagnosis was calculated by subtracting the baseline weight 
from the actual weight. The weight difference was thereafter divided by the 
baseline weight and multiplied by 100. There is no uniform consensus on the 
definition of malnutrition in relation to weight loss, but it has often been referred 
to as >5% in 3 months,188 >10-15% weight loss within 6 months before 
surgery,189 or >10% in the six months before surgery.190 The choice of 10% 
weight loss as the cut-off was pre-defined and chosen based on earlier studies, 
where such weight loss has been found to be associated with increased risk of 
postoperative complications after major abdominal surgery.190 
Study outcome was postoperative course, specified as postoperative 
complications, length of hospital stay and overall survival. Postoperative 
complications were categorised into: 1) early surgical complications, 2) early 
non-surgical complications, and 3) late surgical complications. Length of 
hospital stay was defined as the number of days in hospital since the date of 
the primary operation. Overall survival was calculated from the date of the 
oesophagectomy until death or end of follow-up, which was up to 5 years after 
the operation. Patients were seen in the outpatient clinic every 3rd month during 
the first year after the surgery, every 6th month the second year, and yearly 
thereafter until 5 years after the operation. Imaging was not routinely performed 
only in patients presenting with clinical signs of recurrence.  
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6.3  STATISTICAL METHODS 
Survival: Studies I-II and V 
For Studies I and II survival was calculated using Kaplan-Meier curves. 
Differences in survival between the survival curves of patients were evaluated 
using the log rank test. In a Cox proportional hazards model, hazard ratios (HR) 
with 95% confidence intervals (CI) of mortality were calculated. These analyses 
included adjustment for potential confounding factors in a multivariable model. 
Nine known prognostic factors for increased mortality after oesophagectomy 
were adjusted for. These factors included: 1) age, 2) sex, 3) comorbidity, 4) 
neoadjuvant therapy and 5) calendar period for both studies.  
In Study I analyses were additionally adjusted for: 1) T-stage and 2) annual 
surgeon volume. In Study II analyses were additionally adjusted for: 1) tumour 
stage, 2) histological type of tumour and 3) surgical radicality. 
Missing values on any of the covariates were handled using two strategies in 
the multivariable model: 1) missing data were grouped into a separate category 
or 2) patients with missing data were excluded.191 Since the HR did not differ 
between these two strategies for missing data, only the results from strategy 1 
are presented in the tables and text, since it better preserves the statistical 
power. Moreover, since HR were similar in the adjusted and unadjusted 
analyses, only the adjusted HR are presented.  
In Study V, the odds of unintentional weight loss in relation to surgical and non-
surgical complications were calculated using logistic regression, expressed as 
odds ratios (ORs) with 95% CI. In a multivariable model the OR of surgical and 
non-surgical complications in relation to unintentional weight loss was adjusted 
for potential confounding by: age, sex, tumour stage, comorbidity, and 
neoadjuvant chemo- and/or radiotherapy. Interactions between body mass 
index (BMI) and weight loss were tested in a Wald test. BMI was defined as 
weight prior to operation divided by the patient’s height in metres, to the power 
of two (weight in kilogrammes / height in metres2). Kaplan-Meier curves were 
used to illustrate hospital admission time and overall survival in the comparison 
groups, and the log rank test was used to analyse differences between the 
curves. In a Cox regression model HR with 95% CI regarding hospital 
admission time and overall survival were calculated. In a multivariable model 
 44
the HR of differences in admission time and overall survival for the two weight-
loss groups were adjusted for potential confounders (listed above).   
 
Symptoms measurement:  Studies III-IV 
In Study III and IV symptoms were measured using the QLQ-OES18.192 All 
questions have 4 response categories: 1) not at all, 2) a little, 3) quite a bit and 
4) very much. Responses were further dichotomised into “no- or minor 
symptoms” versus “symptomatic”. Patients who had at least one response of 3 
(‘‘quite a bit’’) or 4 (‘‘very much’’) to any item within a scale were categorised as 
‘‘symptomatic.’’ Otherwise patients were categorised as having ‘‘no or minor 
symptoms in accordance with earlier studies.160, 193 Odds of reporting the 
symptoms were estimated using logistic regression models and were 
expressed as OR with 95% CI. Analyses were adjusted for 1) sex, 2) age, 3) 
tumour stage, 4) histological type of the tumour and 5) comorbidity. Analyses in 
Study III were additionally adjusted for postoperative complications. Study IV 
additionally adjusted for neoadjuvant therapy.  
In Study III the odds of reporting symptoms of reflux and dysphagia were 
measured, according to the above-mentioned methods, in relation to selected 
surgical techniques performed to reduce reflux symptoms (i.e. cervical 
anastomosis, anti-reflux procedure and pyloric drainage procedure). To 
address interactions between the different surgical procedures, the study 
exposures were redefined as follows in a separate analysis: 1) cervical 
anastomosis, 2) pyloric drainage procedure, 3) cervical anastomosis with 
pyloric drainage procedure, 4) antireflux procedure surrounding the 
anastomosis with pyloric drainage procedure, and 5) no additional procedure. 
Propensity-adjusted analyses were performed to adjust for selection bias and 
covariate confounding. Propensity scores were estimated by multinomial 
logistic regression model with the same covariates used in the full model. The 
multinomial logistic regression model was used to address the multi-group 
exposure. In the final step, the propensity score was used as the only covariate 
in multivariable logistic regression models for assessing risk of reflux and 
dysphagia (expressed as OR with 95% CI). 
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In Study IV the odds of relevant symptoms of eating difficulties, odynophagia, 
dysphagia, trouble swallowing saliva and reflux were calculated in relation to 
anastomotic leak. 
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7  RESULTS 
7.1 STUDY I   
During the study period, 1304 patients underwent resection for oesophageal 
cancer in Sweden. After applying exclusion criteria, 1044 patients were left for 
final analysis. Some characteristics of these study participants are presented in 
Table 2. The number of removed and examined lymph nodes ranged from 0 to 
114 with a median of 7. The range of the number of metastatic lymph nodes 
was 0 to 22 with a median of 0. The median ratio between the number of 
metastatic and total resected nodes was 0.03 (range 0 to 1). Eighty-eight 
patients died within the first 90 days after surgery rendering a 90-day mortality 
rate of 8%. The overall absolute 5-year mortality was 81% (848 patients), and 
among those who died, 76% (795 patients) had a recorded tumour recurrence. 
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Table 2. Characteristics of the 1044 study patients included in Study I 
 
  Characteristics Number of patients (%) 
Age (years)  
 64 471 (45.1) 
65-75 415 (39.8) 
>75 158 (15.1) 
Sex  
Male 781 (74.8) 
Female 263 (25.2) 
Comorbidity  
0 516 (49.4) 
1 339 (32.5) 
2 189 (18.1) 
Pathological T-stage  
Tis, T0, T1 376 (36.0) 
T2 210 (20.1) 
T3 373 (35.7) 
T4 29 (2.8) 
Missing data 56 (5.3) 
Histological tumour type  
Squamous cell 552 (59.2) 
Adenocarcinoma 437 (41.8) 
Other 55 (5.3) 
Neoadjuvant treatment  
No 629 (60.3) 
Yes 349 (33.4) 
Annual surgeon volume  
0-9 525 (50.3) 
10 519 (49.7) 
Calendar period   
1987-1992 193 (18.5) 
1993-1998 238 (22.8) 
1999-2004 267 (25.6) 
2005-2010 346 (33.1) 
Number of lymph nodes removed  
1-2nd quartile (0-6) 530 (50.8) 
3rd quartile (7-15) 261 (25.0) 
4th quartile (16-114) 253 (24.2) 
Number of metastatic lymph nodes  
1-2nd quartile (0) 526 (50.4) 
3rd quartile (1-3) 301 (28.8) 
4th quartile (>3) 217 (20.8) 
Ratio of metastatic and removed lymph nodes 
1-2nd quartile (0.00-0.03) 509 (50.1) 
3rd quartile (0.04-0.38) 225 (25.1) 
4th quartile (>0.38) 252 (24.8) 
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A higher number of lymph nodes removed did not decrease the overall 
mortality, disease-specific mortality or the short-term mortality. The linear 
regression analyses did not reveal an influence of a higher number of lymph 
nodes removed on overall 5-year mortality (HR 1.00, 95% CI 0.99-1.01). 
Patients in the third (7-11 nodes) and fourth (12-114 nodes) quartile of removed 
nodes did not have a decreased overall 5-year survival compared to those in 
the lowest two quartiles (6 nodes) (HR 1.17, 95% CI 0.94-1.45, and HR 1.13 
and 95% CI 0.95-1.35, respectively). The T-stage specific results indicated an 
increased HR of mortality in the early T-stages (Tis-T1) (HR 1.61, 95% CI 1.17-
2.23 in the third quartile and HR 1.37, 95% CI 0.95-2.00 in the fourth quartile), 
compared to later stages (T2-T3) (HR of 0.96, 95% CI 0.75-1.21 and HR 1.19, 
95% CI 0.89-1.58, in the third and fourth quartile respectively). (Table 3, Figure 
6) The disease-specific HR were similar to the overall HR. (Table 4) 
 
 
Figure 6. Survival estimates for the number of resected lymph nodes 
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An increasing number of metastatic lymph nodes had, as expected, a strong 
negative influence on the 5-year mortality (Table 5), but not on short-term 
mortality. The HR of overall 5-year mortality in the fourth quartile of metastatic 
lymph nodes (>3 metastatic nodes) was 2.74 (95% CI 2.26-3.39), compared to 
the lowest two quartiles (no metastatic nodes). The HR of overall 5-year 
mortality were slightly higher in lower compared to higher T-stages, but there 
were no statistically significant differences. (Table 3, Figure 7) HR of disease-
specific mortality were similar to those of the overall mortality.  
 
 
Figure 7. Survival estimates for the number of metastatic lymph nodes 
 
As expected, a higher ratio between metastatic and total lymph nodes entailed 
a strongly increased overall 5-year HR of mortality, but not on mortality within 
90 days of surgery. In the third quartile (ratio 0.04-0.38) the HR of mortality was 
1.66 (95% CI 1.39-1-98) compared to the lowest two quartiles (ratio 0.0-0.03). 
In the fourth quartile (ratio >0.38) the HR of overall 5-year mortality was 3.19 
(95% CI 2.65-3.84) compared to the lowest two quartiles. There were no 
differences in mortality between lymph node ratios in the specific T-stage 
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analyses. (Table 3, Figure 8) The HR of disease-specific mortality were similar 
to those of the overall mortality.  
 
 
 Figure 8. Survival estimates for the ratio between metastatic and resected 
lymph nodes
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Table 3. Overall 5-year mortality presented as hazard ratios (HR) with 95% 
confidence interval (CI) in relation to number of resected lymph nodes, 
number of metastatic lymph nodes and ratio of metastatic and resected 
lymph nodes in 1044 patients operated for oesophageal cancer in 1987-
2010 in Sweden 
*Adjusted for potential confounding factors: Age, sex, comorbidity, neoadjuvant 
treatment, surgeon volume and calendar period. 
 All stages (Tis-T4) 
 Number  HR* 95% CI 
Resected lymph nodes 1044   
1st -2nd quartile 0-6 530 1.00  - 
3rd quartile 7-15 261 1.13 0.95-1.35 
4rd quartile 16-114 253 1.17 0.94-1.45 
Metastatic lymph nodes 1044   
1st -2nd quartile 0 526 1.00  - 
3rd quartile 1-3   301 1.91 1.62-2.25 
4rd quartile >3 217 2.74 2.26-3.39 
Ratio of lymph nodes 1016   
1st -2nd quartile  0.0-0-03 509 1.00 - 
3rd quartile 0.04-0.38 255 1.66 1.39-1.98 
4rd quartile >0.38 252 3.19 2.65-3.84 
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Table 4. Overall 5-year disease-specific mortality, presented as hazard ratios 
(HR) with 95% confidence intervals (CI), in relation to number of removed lymph 
nodes, number of metastatic lymph nodes and lymph node ratio in 1044 patients 
operated for oesophageal cancer in 1987-2010 in Sweden. 
 
*Adjusted for potential confounding by: age, sex, comorbidity, neoadjuvant treatment, 
surgeon volume and calendar period
 All tumour stages (Tis-T4) 
 Number HR* 95% CI 
Resected lymph nodes    
1st -2nd quartile 0-6 459 1·00 - 
3rd quartile 7-15 180 1·15 0·94-1·42 
4rd quartile 16-114 156 1·19 0·90-1·57 
Number of metastatic lymph 
nodes 
   
1st -2nd quartile 0 381 1·00 - 
3rd quartile 1-3 233 2·22 1·81-2·70 
4rd quartile >3 181 2·82 2·25-3·53 
Ratio lymph nodes    
1st -2nd quartile 0·0-0·03 361 1·00 - 
3rd quartile 0·04-0·38 181 1·95 1·56-2·42 
4rd quartile >0·38 227 3·02 2·45-3·71 
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7.2 STUDY II 
During the study period we identified 2195 patients who were eligible for 
inclusion in the study cohort. After exclusion of 373 patients (17%) where 
medical records were not available, 1822 (83%) patients remained for final 
analysis. Of these, 200 patients (11%) underwent a reoperation (in total 248 
reoperations) within 30 days of the primary oesophageal resection. (Table 5) As 
shown in Table 6 there were no major differences in characteristics between 
the patients who did and did not undergo such reoperation.  
 
Table 5. Categorisation of the 248 reoperations within 30 days after initial 
surgery in a cohort of 1822 patients undergoing oesophagectomy between 1987 
and 2010 in Sweden, with follow-up until 28th February 2012. 
 
 
  Type of reoperation Number (%) 
Total number of reoperations 248 (100) 
Explorative laparotomy 47 (19) 
Explorative thoracotomy 11 (4) 
Reoperation for bleeding 22 (9) 
Reoperation for anastomotic insufficiency 43 (17) 
 Laparotomy 3 
 Thoracotomy 1 
 Unknown/other 39 
Reoperation for infection 8 (3) 
Reoperation for wound revision 50 (20) 
 Wound revision for 
bleeding 
15 
 Wound revision for 
infection 
5 
 Wound dehiscence 7 
 Unknown 23 
Other reoperations 75 (30) 
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Table 6. Characteristics of the 1822 patients included in Study II 
 
Characteristic Number of patients (%) 
 No reoperation Reoperation 
Total 1622 (89) 200 (11) 
Sex   
Men 1211 (75) 151 (75) 
Women 411 (25) 49 (25) 
Age   
64 754 (46) 93 (47) 
65-75 615 (38) 78 (39) 
>75 253 (16) 29 (14) 
Comorbidity*   
None 832 (51) 107 (54) 
1 542 (34) 63 (31) 
2 248 (15) 30 (15) 
Stage‡   
0-I 339 (20) 41 (20) 
II 532(33) 71 (35) 
III 399 (25) 46 (23) 
IV 127(8) 13 (7) 
Missing† 225 (14) 29 (15) 
Histology   
Adenocarcinoma 645 (40) 70 (35) 
Squamous cell carcinoma 880 (54) 123 (62) 
Missing† 97 (6) 7 (3) 
Neoadjuvant therapy   
None 677 (42) 85 (43) 
Radiotherapy 154 (9) 26 (13) 
Chemoradiotherapy 302 (19) 35 (17) 
Missing† 489 (30) 54 (27) 
Radicality   
R0 1135 (69) 137 (68) 
Not R0 251 (16) 30 (15) 
Missing † 236 (15) 33 (17)  
Hospital volume   
<9 per year 875 (54) 122 (61) 
9 per year 747 (46) 78 (39) 
Calendar period   
1987-1990 234 (14) 34 (17) 
1991-1994 302 (19) 43 (22) 
1995-1999 330 (20) 49 (25) 
2000-2005 382(24) 37 (19) 
2006-2010 374 (23) 37 (19) 
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Among the 208 patients (11%) who died within 90 days of surgery, 54 (26%) 
underwent reoperation. Reoperation was a risk factor for such short-term 
mortality even after adjustment for confounding factors (HR 3.05, 95% CI 2.22-
4.17). Among the 1276 (79%) patients who died between 90 days and 5 years 
after surgery, 117 (10%) were reoperated upon. The log-rank test comparing 
the Kaplan-Meier survival curves of patients with and without reoperation 
between 90 days and 5 years after surgery revealed an increased mortality in 
the first group (p<0.0001). Additionally there was a 27% increased adjusted HR 
of mortality during the period 90 days to 5 years after surgery among 
reoperated patients (HR 1.27, 95% CI 1.05-1.53). (Table 7, Figure 9)  
 
 
 
Figure 9. Survival estimates for patients who did and did not undergo a 
reoperation 
 
In a subgroup analysis of the 3 most common types of reoperations, i.e. 
exploratory laparotomy, reoperation for anastomotic insufficiency and wound 
revision, the point HR were increased for each type of reoperation, (Table 4) 
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and patients reoperated upon for anastomotic insufficiency in particular had an 
increased HR of mortality (adjusted HR 1.82, 95% CI 1.19-2.76). (Table 8) 
 
Table 7.  Hazard ratios (HR) with 95% confidence intervals (CI) of mortality after 
oesophagectomy with respect to occurrence of reoperation, based on 1822 
patients undergoing oesophageal cancer surgery in 1987-2012 in Sweden 
*Adjusted for sex, age, co-morbidities, tumour stage, histology, neoadjuvant therapy, 
radicality, hospital volume, and calendar period. 
†Missing values of covariates were missing at random and considered as a separate 
group. 
‡Event means death 
 
Table 8. Hazard ratios (HR) with 95% confidence intervals (95% CI) of mortality 
between 90 days and 5-years in a subgroup analyses of the most common types 
of reoperations after oesophagectomy, based on 1822 patients undergoing 
oesophageal cancer surgery in 1987-2012 in Sweden 
 
Type of reoperation Number of 
patients (%) 
HR (95% CI) *, † 
Exploratory laparotomy 47 (19) 1.17 (0.82-1.67) 
Reoperation for 
anastomotic insufficiency 
43 (17) 1.82 (1.19-2.76) 
Wound revision 50 (20) 1.32 (0.87-2.00) 
*Adjusted for sex, age, co-morbidities, tumour stage, histology, neoadjuvant therapy, 
radicality, surgeon volume, and calendar period. 
†Missing values of covariates were missing at random and considered as a separate 
group. 
 
 
Number of 
patients (%) 
Number of 
events (%)‡ 
HR (95% CI) 
All stages    
<90 days  1822 (100) 208 (11)  
Crude   3.17 (2.32-4.32) 
Multivariable*,†   3.05 (2.22-4.17) 
    
90 days – 5 
years  
1614 (89) 1276 (79)  
Crude   1.22 (1.02-1.47) 
Multivariable*, †   1.27 (1.05-1.53) 
    
>5 years  338 (19) 127 (37)  
Crude   0.51 (0.21-1.25) 
Multivariable*,†   0.42 (0.17-1.07) 
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7.3 STUDY III 
In total 616 patients were included in the entire SECC cohort. During the first 6 
months after surgery 111 (18%) patients had died and another 103 (17%) were 
unable to participate at the 6-month postoperative outcome assessment. 
Among the remaining 402 patients, we excluded 37 (9%) patients with non-
gastric substitute, 58 (13%) patients without an intrathoracic or cervical 
anastomosis, and 3 (1%) patients who did not answer the questions relevant for 
this study. Thus leaving 304 patients for final analyses. There were no major 
differences between the comparison groups regarding sex and age distribution, 
squamous cell carcinoma was overrepresented in patients with a cervical 
anastomosis, and there were more complications in the group with cervical 
anastomosis compared to those with intrathoracic anastomosis. (Table 9) 
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Seven out of 30 (23%) patients with a cervical anastomosis and 75 out of 274 
(27%) patients with an intrathoracic anastomosis experienced reflux symptoms 
6 months postoperatively. There was no statistically significantly decreased OR 
of reflux symptoms when a cervical anastomosis was created, compared to an 
intrathoracic anastomosis (OR 0.86, 95% CI 0.32-2.23). (Table 10) Reflux 
symptoms were reported by 10 out of 42 (24%) of the patients with an antireflux 
anastomosis and 65 out of 232 (28%) of the patients with a conventional 
anastomosis, rendering no decreased risk of reflux symptoms in patients with 
an antireflux anastomosis compared to those without (OR 0.86, 95% CI 0.39-
1.90). (Table 10) Reflux symptoms were reported by 54 out of 184 (29%) 
patients with a pyloric drainage procedure and by 28 out of 120 (23%) without 
any pyloric drainage procedure, and the adjusted OR of reflux symptoms was 
not decreased with pyloric drainage (OR 1.49, 95% CI 0.86-2.58). (Table 10) 
In the propensity-adjusted analysis no decrease in OR of reflux symptoms was 
found for any of the individual types or combinations of surgical procedure. 
(Table 3) Moreover, there was an increased OR of dysphagia (OR 10.34, 95% 
CI 1.19-89.91) with a cervical anastomosis, but no increased risk for dysphagia 
with any of the other surgical procedures. (Table 11)  
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7.4 STUDY IV 
Among 616 patients included in this study, 111 (18%) died before the six-month 
follow-up, and 103 (20%) declined or were too ill to participate. Among the 
remaining 402 patients, 125 were excluded because the anastomosis was not 
intrathoracic or they were not reconstructed with a gastric conduit. Some 277 
patients (70% of eligible) remained in the final cohort. Of these, 29 (11%) had 
an anastomotic leak.  At 3 years after surgery 103 patients remained. Some 
characteristics are presented in Table 12.  
Compared to patients without an anastomotic leak, those with a leak had a 4-
fold increased risk of difficulty eating (OR 4.05, 95% CI 1.47-11.16) and a more 
than 2-fold increased risk of odynophagia (OR 2.59, 95% CI 1.15-5.82) 6 
months after surgery. Patients with an anastomotic leak had a two-fold 
increased point OR of trouble swallowing saliva, but this risk was not 
statistically significant (OR 1.98, 95% CI 0.58-6.67). There was no increased 
risk of dysphagia or reflux after intrathoracic anastomotic leak. (Table 13) At 3 
years after surgery, the risk of eating difficulties remained increased with an OR 
of 5.78 (95% CI 1.03-32.39). The increased risk of odynophagia was persistent, 
however it was not statistically significant (OR 2.41, 95% CI 0.46-12.38). There 
was no increased risk for trouble swallowing, dysphagia or reflux 3 years after 
surgery. 
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7.5 STUDY V 
During the study period, 1271 patients with cancer of the oesophagus or 
gastro-oesophageal junction were considered for surgical resection in the 
Erasmus MC Rotterdam, the Netherlands. Exclusions were made for the 
following reasons: the primary plan (surgical tumour resection) was not pursued 
(235 [18%] patients), different histology (17 [1%] patients) and missing 
information on explanatory variables (67 [5%] patients). Of the 922 remaining 
patients (73%), 155 (17%) lost >10% of their usual weight in the 3 months prior 
to diagnosis and were thus classified as exposed. Patients with non-radical 
resections, i.e. R1 and R2 resections (336 [26%] patients) were excluded from 
the long-term survival analyses, but were included in the short-term outcome 
analyses e.g. length of hospital stay, postoperative mortality and early surgical-, 
non-surgical and long-term complications. Patient and tumour characteristics of 
exposed and non-exposed patients are shown in Table 14. 
A total of 249 (27%) patients developed a surgical complication within 30 days 
of surgery. There was no increased risk of such early surgical complications 
comparing patients with and without weight loss (adjusted OR 0.83, 95% CI 
0.54-1.24) (Table 15-16) and there was no increased risk of anastomotic leak 
(adjusted OR 0.87, 95% CI 0.46-1.64), wound infections (adjusted OR 95% 
1.10, 95% CI 0.47-2.45) or necrosis of the substitute (adjusted OR 1.10 95% 
0.34-13.20). (Table 15) Some 472 (51%) patients developed an early non-
surgical complication. There was no increased risk of such complications when 
comparing the exposed with the non-exposed groups (adjusted OR 0.90, 95% 
CI 0.63-1.30). (Table 15-16) Late surgical complications were diagnosed in 327 
(35%) patients. No increased risk was identified in patients with weight loss. 
(Table 16) The mean admission time was 22 days (standard deviation 20.9) 
and 20 days (standard deviation 15.3) for patients with and without weight loss, 
respectively. (Table 15)  
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Table 14. Characteristics of 922 patients who had undergone oesophageal 
cancer resection, with or without >10% weight loss during 3 months prior to 
diagnosis. 
 Number (%) 
Variable Total 
 
Weight 
loss 10% 
Weight 
loss 
>10% 
Total 922 
(100) 
767 (83) 155 (17) 
Age    
Mean (SD) 63 (10) 62 (10) 60 (10) 
Sex    
Male 712 (77) 609 (79) 103 (66) 
Female 210 (23) 158 (21) 52 (34) 
Body mass 
index* 
   
<25 419 (45) 324 (48) 95 (75) 
25-29 285 (31) 260 (39) 25 (20) 
30 95 (10) 88 (13) 7 (6) 
Missing 89 (13) 73 (13) 16 (15) 
Comorbidity†    
None 421 (46) 360 (47) 61 (40) 
One or more 501 (54) 407 (53) 94 (61) 
Neoadjuvant 
treatment 
   
No 721 (79) 601 (78) 120 (77) 
Yes 201 (22) 166 (22) 35 (23) 
Histology    
Squamous cell 263(25) 223 (29) 60 (37) 
Adenocarcinoma 622 (69) 527 (69) 95 (61) 
Adenocarcinoma 
in Barrett’s 
epithelium 
17 (2) 17 (2) 0 (0) 
Tumour stage‡    
0-I 173 (19) 162 (21) 11 (7) 
II 257 (28) 212 (28) 45 (29) 
III 432(47) 342 (45) 90 (58) 
IV 10 (1) 6 (1) 4 (30 
Unknown 49 (7) 45 (7.8) 4 (4) 
    
Surgical 
approach 
   
Transhiatal 722(79) 610 (80) 112 (73) 
Transthoracic 169 (18) 135 (18) 34 (22) 
Other§ 28 (3) 20 (3) 8 (5) 
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Table 15. The postoperative course after oesophagectomy for cancer of 922 
patients, with or without >10% weight loss during 3 months prior to diagnosis. 
 
Variable Number (%) 
  Total 
 
Weight loss 
10% 
Weight loss 
>10% 
Length of 
hospital stay 
(days)* 
Mean (SD) 22 (21) 22 (21) 20 (15) 
Postoperative 
mortality† 
Number 71 (8) 55  (77) 16 (10) 
Early surgical 
complications‡ 
None 674 (73) 556 (60) 118 (13) 
 One or more 249 (27) 212 (23) 37(4) 
Early non-
surgical 
complications§ 
None 450 (49) 370 (40) 80 (9) 
 One or more 473 (51) 398 (43. 75 (8) 
Late surgical 
complications || 
None 570 (63) 468 (53) 92 (10) 
 One or more 327 (37) 267 (30) 60 (7) 
*Admission time in days calculated from day of operation until discharge. 
†Defined as: death within 90 days after surgery. 
‡  Early surgical complications were defined as: complications occurring within 30 days 
of initial surgery, including anastomotic leak, recurrent laryngeal nerve paresis or 
paralysis, bleeding, (small) bowel obstruction, chyle leakage, leakage of the feeding 
tube, gastroparesis for >10 days after surgery, wound infection, or necrosis of the 
substitute for which a reoperation was required. 
§ Defined as: ARDS (acute respiratory distress syndrome) thromboembolic events. 
|| Late surgical complications were defined as complications occurring after more than 
30 days after initial surgery, including anastomotic stenosis (requiring dilatation or 
therapy), pyloric stenosis, intercostal neuralgia, ileus, weight loss or cachexia. 
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The Kaplan-Meier curve comparing admission time is shown in Figure 10. 
There was no difference in admission time for patients with and without weight 
loss (log-rank 0.6194). In the adjusted analysis, weight loss did not influence 
admission time (HR 1.06, 95% CI 0.85-1.33). (Table 17) The Kaplan-Meier 
curve comparing patients with and without weight loss regarding overall survival 
of up to 5 years after surgery showed a statistically significantly worse overall 
survival in patients with weight loss (p<0.0001). (Figure 11) After adjustment for 
potential confounders patients with weight loss had a slight increased mortality 
within 5 years after surgery (adjusted HR, 1.34, 95% CI 102-1.74. (Table 17) 
 
 
Figure 10. Admission time for patients with and without preoperative weight loss 
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Figure 11. Overall 5-year survival for patients with and without preoperative 
weight loss
 70
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Table 17.  Impact of preoperative weight loss of >10% prior to oesophageal cancer 
diagnosis on overall and disease-free survival and hospital admission time after 
esophagectomy, expressed as hazard ratios (HR) and 95% confidence intervals 
(CI). 
*Occurrence of an event means death 
† Occurrence of an event means recurrence of disease 
 
 HR 95% CI P-value 
Overall 5-year survival* 1.34 1.02-1.74 0.03 
Admission time 1.09 0.89-1.35 0.41 
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8 DISCUSSION AND METHODOLOGICAL 
CONSIDERATIONS 
8.1 STUDIES I AND II  
Both Studies I and II were conducted from the SESS cohort and therefore have 
similar strengths and flaws. A major strength is the population-based design. 
Virtually all patients who underwent oesophageal cancer resection in Sweden 
between 1987-2010 were included in this cohort rendering an unselected 
sample. Moreover, the large sample size provided sufficient power allowing 
detection of even moderate differences in outcome (mortality) between the 
exposure groups. Another strength is the possibility to adjust for several 
established prognostic factors, which reduces the risk of confounding, which is 
otherwise a threat to observational studies. However, residual confounding by 
the factors adjusted for or unknown factors cannot be entirely ruled out.  The 
exposures and outcomes were predefined and assessed by means of strict 
criteria, which reduces the risk of chance findings and decreases the risk of 
systematic errors owing to misclassification. The retrospective design poses the 
largest problem, since such design introduces an increased risk of 
misclassification of exposures, outcomes and confounding factors. However, 
since the researchers involved in the collection of the clinical data had no link 
with the participating hospitals and were not involved in patient care, this risk 
should be minimal. Moreover, the great efforts to collect and review the medical 
data made the data collection nearly complete and very comprehensive. One of 
the other major sources of bias in follow-up studies is loss to follow-up, 
particularly in cohorts like the SESS cohort, with large sample sizes and long 
follow-up. But since each patient could be linked to the national registers through 
their personal identity numbers, there was virtually no loss to follow-up in this 
cohort.  
 
8.2 STUDIES III AND IV  
Studies III and IV were both conducted within SECC. This cohort, being a 
population-based, nationwide cohort has partly the same advantages and 
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disadvantages as previously mentioned in Studies I and II. An additional 
advantage is the prospective design ensuring a higher accuracy and 
completeness of the data. However, in this cohort there is an additional type of 
bias: non-participation. Of the eligible patients 18% died before the first follow-up 
at 6 months. However, among the patients alive at follow-up the participation rate 
was sufficient; 17% of eligible patients were too sick to participate. This could 
potentially influence results since patients who were sicker and declined 
participation, are more likely to suffer from more severe symptoms. Another 
problem with symptoms assessment is the lack of baseline measures making it 
impossible to adjust for any preoperative symptoms. Finally, there was a lack of 
objective measures to verify reported symptoms, however for many symptoms 
the HRQOL-scales used have been proven sufficient, and for symptoms of 
reflux, subjective assessment is currently the Golden Standard.  
 
8.3 STUDY V  
This study was based on hospital-based data. Since it is a cohort with long 
follow-up, the same limitations apply as in the previous mentioned studies (I and 
II). An additional concern here is that the study is hospital-based, which might 
jeopardize the external validity or generalisability. Referral patterns might provide 
a selection problem. Due to the lack of national guidelines and treatment 
recommendations during most of the years the data was gathered, there were 
hospital policies that might be different from other hospitals.   
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9 INTERPRETATION OF FINDINGS AND 
IMPLEMENTATIONS 
9.1 STUDY I 
Contradictory to our hypothesis, a more extensive lymph node removal did not 
improve overall or disease-specific survival in this patient group. This result 
challenges current recommendations advocating at least two-field 
lymphadenectomy during oesophagectomy.33, 68, 86, 100 The evidence supporting a 
more extensive lymphadenectomy (two-field or three-field lymphadenectomy) is 
limited and based on limited research. However, our results are in line with some 
well-designed studies that compared the extended lymphadenectomy via 
transthoracic oesophagectomy with “limited” lymphadenectomy by a transhiatal 
approach. One large RCT found no survival benefit from a more extensive 
lymphadenectomy, but instead a lower postoperative morbidity in the transhiatal 
group.88, 89 Similarly, a recent large cohort study comparing transthoracic and 
transhiatal resection in 664 patients found no long-term overall survival 
differences between the two approaches.194  Finally, a RCT comparing two-field 
with three-field lymphadenectomy found no difference in survival, while the 
complication rate was increased in the three-field lymphadenectomy group.195 A 
RCT to more in detail assess the extent of lymphadenectomy during 
oesophagectomy is not ethically or practically feasible. Instead guidelines should 
rely on high quality studies based on population-based data like the current 
study. It might be time to reassess the extent of lymphadenectomy during 
oesophagectomy, a development well in line with the history of e.g. breast 
cancer surgery, which was much more extensive in the past.  
 
9.2 STUDY II 
This study suggests that reoperation after primary oesophageal resection 
decreases long-term survival. The finding of the prognostic role of reoperations 
after excluding the initial postoperative period is a finding that should encourage 
further research. It stresses the need for preventive measures to reduce the 
need for reoperation. The results of the subgroup analyses showed that patients 
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undergoing reoperation for anastomotic insufficiency in particular had an 
increased risk of mortality. There is some evidence that anastomotic insufficiency 
entails direct tumour spread and seeding of remaining viable tumour cells in 
colon cancer patients.196, 197 This might explain the higher mortality rate in 
patients with reoperation for anastomotic insufficiency. One biological 
mechanism that might explain the decreased long-term survival after reoperation 
is that the additional surgical injury reduces the protection against seeding of 
tumour cells, including activation of natural killer cells and other anti-carcinogenic 
factors.198 Furthermore, it is possible that additional surgery triggers an elevated 
inflammatory response that might in turn stimulate growth of micro-tumours and 
induce tumour recurrence and death from recurrence.199 Another potential 
mechanism considers certain complications. Blood transfusion has e.g. been 
linked with a worse long-term mortality and increased cancer recurrence in 
different types of cancer. 200-203 Unfortunately, we did not have information on 
blood transfusion in this study, but it can be assumed that patients returning to 
theatre are more likely to receive a blood transfusion, and speculatively, blood 
transfusion may be a mechanism that contributes to the main finding of this 
study. 
 
9.3 STUDY III 
This study indicated that a cervical anastomosis, antireflux anastomosis, and 
pyloric drainage during oesophagectomy do not prevent postoperative reflux 
symptoms after oesophageal cancer surgery. Therefore, such procedures might 
not be generally recommended merely for the purpose of counteracting 
postoperative reflux. Thus, the prevention of reflux symptoms after 
oesophagectomy remains a problem and till today there are no obvious surgical 
solutions to prevent this problem. This issue, that affects over half of the patients 
after oesophagectomy warrants further research. Potent anti-reflux medication is 
usually prescribed to counteract symptoms of reflux, which could counteract at 
least some of the problems. 
of anastomotic leak. 
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9.4 STUDY IV 
In this study, intrathoracic anastomotic leak seemed to increase the risk of eating 
difficulties and odynophagia 6 months after oesophageal cancer resection, and 
symptoms of eating difficulties persisted even 3 years after surgery. A possible 
mechanism is the increased formation of fibrotic scar tissue surrounding the 
gastric conduit and the proximal oesophagus due to inflammation of the 
mediastinum and surrounding tissue caused by a leak. Such fibrotic tissue might 
reduce the elasticity of the conduit.  
These findings can be used to inform patients about the symptoms they might 
encounter after an intrathoracic anastomotic leak, and should be used to alert 
physicians and dieticians responsible for postoperative care to an increased risk 
of malnutrition in this group of patients. More efforts should be made to avoid 
anastomotic leak. Centralisation of services and referral to high-volume centres 
has, for example, been shown to improve outcomes after oesophageal cancer 
surgery and potentially offer a reduced risk of anastomotic leak. 
 
9.5 STUDY V 
Patients with oesophageal cancer who experience weight loss of >10% in the 3 
months before diagnosis had no increased risk of postoperative complications or 
longer hospital stay in this study. However, they had an increased overall 5-year 
mortality after surgery. These results highlight the need for studies to test 
whether improving the nutritional status in malnourished patients with 
oesophageal cancer before oesophagectomy is beneficial from a prognostic 
viewpoint. Weight loss might continue after oesophagectomy.204 This stresses 
the need to actively help oesophageal cancer patients, especially the ones 
treated with surgical tumour resection, to counteract malnutrition from the time of 
diagnosis. Weight loss before diagnosis might not be adjustable since patients 
are not under medical attention. 
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10 CONCLUSIONS 
Study I - A more extensive lymph node resection does not seem to improve the 
5-year survival after oesophagectomy for oesophageal cancer.  
 
Study II - Reoperation might be associated with an increased mortality even 
after the initial 3 months following surgery for oesophageal cancer.  
 
Study III- Cervical anastomosis, antireflux anastomosis, and pyloric drainage 
during oesophagectomy do not seem to prevent reflux symptoms following 
surgery for oesophageal cancer.  
 
Study IV - Intrathoracic anastomotic leak is followed by an increased risk of 
eating difficulties and odynophagia 6 months after oesophagectomy. 
 
Study V - Weight loss of >10% in the 3 months before diagnosis, might increase 
the overall 5-year mortality after surgery for oesophageal cancer.  
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11  FUTURE RESEARCH 
The poor prognosis and persisting symptoms of oesophageal cancer patients 
after treatment with curative intent remains a concern. The implementation of 
multimodal therapy has somewhat improved long-term prognosis, however there 
is a lot of room for improvement. All too often the disease has already spread to 
the lymph nodes or other organs at time of diagnosis. This makes oesophageal 
cancer a systemic disease, warranting improvement in systemic treatment like 
chemotherapy or more targeted therapy. The latter is still highly experimental.  
Several studies have reported a complete pathological response in up to 25% of 
the patients in their study population. This leaves us wondering if there is a place 
for definitive chemoradiotherapy in the treatment plan of oesophageal cancer 
patients. It might be that certain patients benefit from definitive 
chemoradiotherapy while others benefit more from a complete resection. 
Research is needed to provide additional evidence and possible guidelines of 
what patients might benefit from such treatment.  
Unfortunately all too often the disease is already metastasised at the time of 
diagnosis. One reason for this is the late and subtle presentation of symptoms. 
Currently there are no easy accessible methods for the early detection of 
oesophageal cancer. Patients with Barrett’s oesophagus regularly undergo 
endoscopy; however the majority of oesophageal cancer patients have not been 
included in endoscopy surveillance programmes. The disease is too rare to 
implement a population screening for oesophageal cancer. However, high-risk 
patient groups could be defined and might be selected for screening for this 
cancer with regular intervals. This way we might catch more patients at an earlier 
tumour stage, and thus significantly improve the survival. Furthermore, with the 
development of minimally invasive and endoscopic techniques for early 
oesophageal cancer, the postoperative morbidity might be reduced, patient 
satisfaction might increase, and persisting symptoms might reduce. 
Another hot topic within oesophageal cancer surgery is centralisation. Several 
studies have shown that patients operated on by high volume surgeons at high 
volume hospital have a lower risk of complications and better long-term survival 
compared with those who are not. In this thesis we showed a negative influence 
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of reoperation on long-term survival. Reoperation often entails a serious 
postoperative complication, which in turn might be to some extent prevented by 
centralisation to high volume surgeons and hospitals.  
Finally, but most controversially, we might have to challenge the current 
guidelines concerning lymphadenectomy. There is weak scientific evidence of 
the benefit of an extended lymphadenectomy and the results of this thesis 
challenge this. To reduce trauma and postoperative morbidity, a less extensive 
lymph node resection might be appropriate, since it does not seem to prolong 
survival. A lymphadenectomy that enables selective removal of metastatic nodes 
while leaving non-metastatic nodes would probably be ideal, but it might be 
difficult to readily identify metastatic nodes during surgery. Improvements in 
preoperative nodal staging would be beneficial in this respect, since it could 
guide surgeons to remove specific areas of metastatic nodes, but a better 
solution might be to identify biomarkers that can identify metastatic nodes and 
help tailor the nodal removal. Another possibility is to use sentinel node 
techniques, but the multidirectional spread and the high occurrence of skip 
metastasis argue against such approach. A sentinel node mapping procedure 
with 99mtechnetium colloid has been proven efficient in early stage oesophageal 
cancer, but not in later stages. However, no large studies have been performed 
to investigate the feasibility of sentinel node mapping in more advanced cases of 
oesophageal cancer.   
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12 POPULAR SCIENTIFIC SUMMARY (ENGLISH) 
12.1  BACKGROUND 
Oesophageal cancer is a relatively rare disease in the Western world, but 
worldwide it is the 8th most common type of cancer, and the 6th most common 
cancer death. Yet, the number of new patients is increasing. The cause of this 
increase is partly unknown. In Sweden approximately 450 patients are 
diagnosed with oesophageal cancer yearly.  
Most patients diagnosed with oesophageal cancer present to their doctor with 
complaints of unwanted weight loss, fatigue and trouble eating and swallowing. 
They often complain of food getting stuck in the oesophagus during their meals. 
Unfortunately, oesophageal cancer typically causes symptoms in an advanced 
stage. By the time the patients have developed these symptoms and go to their 
doctor, their oesophageal cancer is often already spread to lymph nodes or 
other organs. Therefore, the prognosis is poor. Generally only 5-15% of the 
patients survive for 5 years after diagnosis.  
The most common and most established curatively intended treatment for 
cancer of the oesophagus includes surgery. Nowadays, most patients also 
receive chemotherapy or radiochemotherapy before their operation. During the 
operation the larger part of the oesophagus is removed to make sure that the 
tumour is removed as a whole with reasonable margins. The surgeon then 
creates a tube from the stomach, pulls it up through the diaphragm and chest 
and attaches it to the part of the oesophagus that is left after the tumour is 
removed; the surgical attachment is known as an anastomosis. This operation 
is extensive and complications are quite common. The recovery time after 
surgery is long and a lot of patients still have trouble with symptoms, like reflux, 
nausea and trouble eating, long after the operation is performed.  
This thesis focuses on surgical techniques that might improve survival and 
decrease suffering among oesophageal cancer patients who undergo surgical 
treatment.  
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12.2 METHODS  
This thesis is built of 5 studies (I-V) 
For this thesis we used three data sources. In Studies I and II we used a large 
database (the Swedish Esophageal Cancer Surgery Study, or SESS) with 
patient information that was collected from all hospitals in Sweden operated on 
for oesophageal cancer between 1987 and 2010. The patients were identified 
from the nationwide Swedish Cancer Registry and the Swedish Patient 
Registry. Researchers from our group obtained the operation charts and 
pathology reports to collect information on the operation and tumour, 
respectively. All data were assembled afterwards in a large database.  
In Studies III and IV we used the information of patients who were treated for 
oesophageal cancer between 2000 and 2005 (The Swedish Esophageal and 
Cardia Cancer or SECC database). A Swedish network of surgeons and other 
specialists involved in the care of oesophageal cancer patients made the 
collection of this data possible. Patients were identified shortly after they had 
been diagnosed with the cancer through collaboration with the pathology 
departments of the participating hospitals. The SECC database contains details 
on the tumour, surgical procedures and complications. Additionally, patients 
were asked to fill in a health-related quality of life (HRQOL) assessments at 6 
months, 3 years and 5 years after their operation.  
In Study V we used a database of patients from the Erasmus MC University 
Medical Center in Rotterdam, The Netherlands, including patients from 1978 
and onwards. In this study we used only patients operated on for oesophageal 
cancer between 1990 and 2010. Information on patient demographics, clinical 
and pathologic information, and details of the received treatment, and 
postoperative course were obtained from medical records by a specialised data 
manager. 
In Study I we investigated if it matters how many lymph nodes you remove from 
patients who are operated for oesophageal cancer. In Study II we addressed 
the question if oesophageal cancer patients who undergo a reoperation due to 
a complication within 30 days of surgery, have a shorter long-term survival 
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compared with those who were not reoperated. In study III we tried to assess 
whether reflux after oesophageal cancer surgery can be prevented surgically by 
creating: 1) an anastomosis in the neck, 2) an anti-reflux anastomosis (in the 
chest) or 3) an incision in the outlet of the stomach (pyloromyotomy) to improve 
the emptying of the stomach. In study IV we compared certain symptoms after 
an oesophageal cancer surgery among patients with a leaking anastomosis in 
their chest with those who did not have a leaking anastomosis. In study V we 
assessed the postoperative course of patients with more than 10% weight loss 
in the 3 months before they were diagnosed with oesophageal cancer.  
In Studies I, II and V we measured the risk of death of all causes within 5 years 
of surgery as well as death of patients who suffered from the disease again. 
The risk of death was calculated using a statistical method (called Cox 
proportional hazard method), including adjustment for influence of various 
factors that might confound any associations. In Studies III and IV the selected 
symptoms were measured using a self-administered questionnaires developed 
to assess common symptoms in cancer patients in general (the EORTC QLQ-
C30) and a module assessing specific oesophageal cancer symptoms (the 
EORTC QLQ-OES18). We calculated the risk of symptoms (yes or no) when 
comparing the patients in the different groups. The risk of these symptoms was 
calculated using a statistical method (called logistic regression) and the relative 
risk was presented as odds ratios (OR) with 95%CI. 
Results 
Study I  included 1044 patients. The main finding was that the number of lymph 
nodes that are removed during surgery did not influence survival. This is 
contradictory to current guidelines that advise removal as many lymph nodes 
as possible close to the oesophagus to improve survival. 
Study II included 1.481 patients who underwent oesophageal cancer surgery 
between 1987 and 2010. In total 155 (11%) patients were reoperated within 30 
days of their first operation due to a severe complication. Reoperated patients 
had a 27% higher risk of dying in the 5 years after surgery after excluding the 
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initial 90 days of surgery and patients with a leaking anastomosis had the 
highest risk of such mortality (82% increased) 
In Study III we included 274 patients. Thirty of those (10%) had an anastomosis 
in the neck, 42 (14%) had an anti-reflux anastomosis and 184 (64%) under 
went a pyloromyotomy. None of these techniques alleviate symptoms of reflux 
after oesophageal cancer operation. 
We included 277 patients in Study IV. Of those patients 29 (10%) had suffered 
from a leaking anastomosis in the chest. We found that after such a leak 
patients had a 4-fold increased risk of developing trouble eating a more than 2-
fold risk of pain when swallowing still 6 months after surgery. The difficulties 
eating were still present 3 years after surgery.  
In Study V 922 patients were included during the period 1990-2010. Among 
these 155 (17%) lost more than 10% of their weight in the 3 months before they 
were diagnosed with oesophageal cancer. The patients who lost more than 
10% of their weight did not have any increased risk of complications or any 
longer hospital stay than those who did not loose that much weight. However, 
they did have a 34% higher risk of mortality within the first 5 years after surgery. 
 
12.3 CONCLUSIONS  
Study I: A higher number of removed lymph nodes does not seem to lower the 
risk of death after surgery for oesophageal cancer. It might be justified to review 
the current guidelines that advise to remove a larger number of lymph nodes.  
Study II: Patients who undergo a reoperation for a complication within the first 
30 days of oesophageal cancer surgery have an increased risk of death in the 
first 5 years after surgery even after excluding the initial postoperative period. 
This risk is seemingly especially high in patients reoperated for a leaking 
anastomosis. 
Study III: An anastomosis in the neck, an anti-reflux anastomosis, or a 
pyloromyotomy do not seem to decrease the risk of reflux symptoms 6 months 
after oesophageal cancer surgery.  
  84
Study IV: Patients suffering from a leaking anastomosis seem to have an 
increased risk of persisting symptoms of eating difficulties and pain while 
swallowing 6 months after surgery, and the eating difficulties seem to persist 
still after 3 years.  
Study V: More than 10% weight loss in the 3 months before oesophageal cancer 
diagnosis is followed by an increased risk of death in the first 5 years after 
surgery, but does not influence the risk of symptoms or the length of the hospital 
stay.   
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13  POPULÄR VETENSKAPLIG SAMMANFATTNING 
(SVENSKA) 
 
13.1 BAKGRUND 
Matstrups- och magmuncancer är ovanliga sjukdomar i västernvärlden, men 
matstrupscancer är den åttonde mest vanliga form av cancer I världen.  
 I västernvärlden (USA, Europa, Australien och Ny Zealand) antalet patienter 
med matstrups- och magmuncancer ökar. Anledningen till ökat antal patienter är 
oklart. I Sverige blir ungefär 620 patienten diagnosticerad med matstrups-och 
magmuncancer varje år.  
Patienter som blir diagnosticerat med matstrupscancer presenterar sig oftast 
med svälj svårigheter, trötthet och viktminskning. Dem klagar över mat som 
fastnar bakom bröstbenet efter dem har sväljt maten. Tyvärr get matstrupscancer 
symptom i ett sent skede och blir dem flesta diagnostiserad med sjukdomen när 
den redan har spridit ut sig till lymfkörtlar eller genom kroppen. På grund av detta 
är överlevnad av matstrupscancer patienter mycket dåligt, 5-15% lever 5 år efter 
diagnosen. Det mest vanliga och mest etablerade behandling för cancer är 
kirurgisk tumör resektion. Idag få patienterna oftast cellgift- eller strålbehandling 
eller en combination av dem två, innan operation. Operationen innebär ett 
ingrepp i båda bukhåla och brösthåla. Under operationen ta man bort tumören 
och en stor del av matstrupen för att säkerställa borttagning av hela tumören. 
Kirurgen som opererar patienten skapar en ny matstrupe från magsäcken och 
koppla den delen från matstrupen som är kvar till magsäcken (kopplingen heter 
anastomosen). Operationen är bland den mest avancerade och påfrestande 
ingrepp som genomförs och komplikationer är därför mycket vanligt efter 
ingreppet. Det är en anledning till att bara 31 % av patienter är vid liv 5 år efter 
operation. Återhämtningen efter operation är mycket lång och visse besvär som 
patienter har efter operation är kvarstående. Besvär patienter kan ha lång efter 
matstrupscancer kirurgi är bland annat reflux, illamående, kräkningar och ät-
svårigheter.  
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Det här avhandling fokuserar på kirurgiska tekniker som kan förbättra överlevnad 
hos matstrupscancer patienter och kan förebygga kvarstående besvär. Målet 
med avhandlingen är att hitta den tekniken som är optimalt för överlevnad och 
som minskar kvarstående besvär. 
 
13.2 METODER 
Avhandlingen är uppbyggt kring fem delarbeten (I-V) 
För delarbete I och II använder vi en stor databas (The Swedish Esophageal 
Cancer Surgery Study, eller SESS) med patient uppgifter insamlades in från alla 
sjukhus som opererade patienter för matstrupscancer, mellan 1987 och 2010. 
Patienterna blev identifierade med hjälp av länkningen mellan de nationellt 
heltäckande Cancerregistret och Patientregistret. Forskare från vår grupp 
samlade i operationsberättelsen, patient uppgifter och patologisvar och 
abstraherade så mycket detaljer som möjligt. Data samlades in i elektronisk i en 
stor databas.  
I delarbete III och IV använder vi information av patienter som fick behandling för 
matstrupscancer mellan 2000 och 2005 (Swedish Esophageal and Cardia 
Cancer or SECC databas). Ett nätverk av Svenska läkare som är involverade i 
behandling av matstrupscancer patienter underlättade insamlingen av data. 
Patienterna identifierades efter diagnostisering i sammanarbeta med patologi 
avdelningen av dem deltagande sjukhus. SECC databasen innehåller detaljer 
om tumören, operation och komplikationer. Dessutom samlades information in 
om patienternas hälso-relaterade livskvalitet vid tre tillfällen (6 månader, 3 år och 
5 år efter operationen).  
 I delarbete V använder vi en sjukhus baserad databas från Erasmus MC 
Universitets sjukhus is Rotterdam, Nederländerna. Läkarna har samlat i data från 
matstrupscancer patienter sedan 1978 och insamlingen är pågående. I detta 
delarbete använder vi patienter som blev opererade mellan 1990 och 2010. 
Information om patientkaraktäristika, kliniska och patologi uppgifter samt 
information om behandling, operation och postoperativa belopp abstraherades 
från patientjournaler.   
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I delarbete I undersökte vi påverkan av antalet borttagna lymfkörtlar på 
överlevnad i patienter som blev opererade för matstrupscancer kirurgi. Vår 
hypotes var att desto flera lymfkörtlar man ta bort, desto bättra överlevnaden.  
I delarbete II försökte vi att svara på frågan om reoperation på grund av 
komplikationer, inom 30 dager efter matstrupscancer kirurgi, påverkar den 
långsiktiga överlevnaden jämfört med patienter som inte blev reopererade. 
I delarbete III syftade vi att hitta en lösning till kvarstående reflux besvär efter 
matstrupscancer operation. Vi tittade på tre olika kirurgiska tekniker 1) en 
anastomos i halsen, jämfört med en anastomos i bröstet, 2) en antireflux 
anastomos, jämfört med en vanlig anastomos, och 3) ett litet snitt i magsäckens 
utgång som underlättar flöde från magsäcken till tarmen (snittet kallas for 
pyloromyotomi).   
I delarbete IV tittade vi vilka symptom och besvär var kvarstående 6 månader 
efter operation, i patienter som hade haft en anastomos läckage i bröstkorgen. Vi 
tittade på reflux symptom, smärta när man sväljer, svårigheter att äta och svårt 
att svälja. Vi jämförde patienter som hade genomgott ett läckage med dem som 
inte hade det.  
I delarbete V har vi jämfört det postoperativa beloppet av patienter som hade gott 
mer än 10 % ner i vikt i dem 3 månader innan diagnosen och dem som inte har 
gott mer än 10 % ner i vikt.  Vi tittade på postoperativa komplikationer, 
överlevnad och vårdtid   
I delarbete I, II och V har vi kalkylerad risken att dö av alla anledningen och död 
av tumör återfall i dem första 5 år efter operation. Risken att dö kalkylerades med 
statistiska metoden ”Cox proportional hazard”. Vi presenterar risken att dö som 
hazard ratios (HR) med konfidens intervaller (95 % CI) och procent (%). I 
delarbete III och IV har vi mättat dem utvalda symptom med en enkät som är 
utvecklad att mäta symptom som är vanliga hos cancer patienter (EORTC QLQ-
C30) och en modul som mäter symptom som är vanliga i matstrupscancer 
patienter (EORTC QLQ-OES18). Enkäterna används ofta i olika sammanhang 
och är mycket tillförlitliga. En analys metod som heter logistic regression 
användes för att beräkna risk (OR) för symptom. 
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13.3 RESULTAT  
Delarbete I inkluderade vi 1044 patienter. Resultaten visade att antalet borttagna 
lymfkörtlar inte påverkar överlevnad. Dem nuvarande riktlinjer råder att ta bort så 
många lymfkörtlar som möjligt för att förbättra överlevnaden. Men vår studie 
bekräftar inte detta. Patienter där flera lymfkörtlar var borttagna hade ingen lägre 
risk att dö, jämfört med dem där få lymfkörtlar har tagits bort. (HR 1.13, 95 % CI 
0.95-1.01). Resultatet visade att dem som hade flera involverade lymfkörtlar 
(lymfkörtlar med metastas) hade en högre risk att dö av 275 % (HR 2.74, 95 % 
CI 2.26-3.39) inom 5 år efter operationen.  
I delarbete II blev 1481 patienter inkluderade, som genomgick operation för 
matstrupscancer mellan 1987-2010. Totalt 155 (11 %) av patienterna blev 
reopererade inom 30 dagar efter första operation, på grund av alvarliga 
komplikationer. Dessa patienter hade ett 26 % ökad risk att dö nom 5 år jämfört 
med dem som inte blev reopererade. Patienter som blev reopererade på grund 
av ett anastomos läckage hade högsta risk att dö inom 5 år (82 %, HR 1.82, 95 
% CI 1.19-2.76). 
I delarbete III 274 patienter blev inkluderade. Trettio av dem (9.9%) hade en 
anastomos i halsen; fyrtiotvå hade en antireflux anastomos (13.8%) och 
etthundraåttiofyra hade genomgott en pyloromyotomi (64 %). Resultaten visade 
ingen skillnad i reflux symptoms, som 23-29% av patienterna rapporterade. 
Värken en hals anastomos, antireflux anastomos eller pyloromyotomy verkar 
skydda patienter mot reflux besvär efter operation.  
Vi inkluderade 277 patienter i delarbete IV. Bland dessa patienter 29 (10 %) 
hade haft en anastomos läckage i bröstet. Resultat visade att dem som hade 
haft en anastomos läckage hade en fyra gånger ökad risk av kvarstående besvär 
med att äta (OR 4.1, 95 % CI 1.2-11.2) och en två gånger ökad risk att få svårt 
att svälja (OR 2.6, 95% CI 1.1-5.8) sex månader efter operationen. Svårigheter 
att äta var ett kvarståendet besvär, efter 3 år var risken för detta i patienter med 
anastomos läckage fortfarande ökad (OR 2.0, 95 % CI 1.0-32.4). 
I delarbete V 922 patienter inkluderades under perioden 1990-2010. Bland dem 
922, 155 (17 %) tappade fler än 10% av deras vikt under dem senaste 3 
månader innan diagnosen. Vi såg att dem som hade tappad så mycket vigt hade 
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ingen ökad risk för postoperativa komplikationer (OR 0.83, 95 % CI 0.54-1.24) 
och vårdtid än dem som inte tappade så vikt (HR 1.06, 95 % CI 0.85-1.33). Dem 
hade dock en ökad risk mycket att dö inom dem första 5 år efter operationen (HR 
1.34, 95 % CI 1.02-1.72) 
 
13.4 SLUTSATSER 
Delarbete I: Ett större antal borttagna lymfkörtlar minskar inte risken att dö inom 
5 år efter matstrupscancer operation. Vi kan därför ifrågasätta gällande riktlinjer 
som råder att ta bort så många lymfkörtlar som möjligt. Som förväntat, ökar ett 
större antal involverade lymfkörtlar (dem med metastaser) risken att dö inom 5 år 
efter operation.  
Delarbete II: Patienter som blev reopererade inom 30 dagar efter 
matstrupscancer operation hade en 27 % ökad risk att dö inom 5 år. Risken var i 
synnerhet ökar i patienter som blev reopererade för anastomos läckage (82 %). 
Delarbete III: Värken en anastomos i halsen, en antireflux anastomos eller en 
pyloromyotomy skyddar mot reflux symptom 6 månader efter matstrupscancer 
operation.  
Delarbete IV: Patienter som hade haft en anastomos läckage hade en ökad risk 
för att utveckla ät svårigheter och smärta när man sväljer 6 månader efter 
operation. Risken för att utveckla ät svårigheter är kvarstående 3 år efter 
operation. 
Delarbete V: Mer än 10 % viktminskning i dem senaste 3 månader innan 
matstrupscancer diagnosen ökar inte risken för postoperativa komplikationer 
eller längre vård tid, men ökar dock risken att dö inom 5 år efter operation. 
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14 POPULAIR WETENSCHAPPELIJKE SAMENVATTING 
(NEDERLANDS) 
14.1 ACHTERGROND 
Slokdarmkanker en maagmondkanker zijn relatief zeldzame aandoeningen in 
de westerse wereld, maar wereldwijd staan ze op de achtste plek in de lijst van 
meest voorkomende vormen van kanker. In de westerse wereld (VS, Europa, 
Australi­, Nieuw-Zeeland) stijgt het aantal patiënten dat wordt gediagnostiseerd 
met slokdarmkanker. De reden hiervoor is tot nog toe onduidelijk. In Zweden 
worden jaarlijks ongeveer 620 pati­nten gediagnostiseerd met slokdarm- of 
maagmondkanker. De meeste pati­nten melden zich bij hun arts met klachten 
van gewichtsverlies, vermoeidheid en problemen met slikken. Vaak klagen ze 
over eten dat achter het borstbeen blijft hangen. Helaas geeft slokdarmkanker 
pas laat klachten en worden de meeste patiënten gediagnostiseerd als de 
ziekte zich al naar de lymfeklieren of naar andere organen heeft uitgezaaid. 
Omdat pati­nten pas zo laat gediagnostiseerd worden is de prognose vaak 
slecht: de kans op vijf jaar overleving ligt rond de 5-15% voor alle 
slokdarmkanker pati­nten. Over het algemeen wordt slokdarmkanker 
behandeld met een chirurgische ingreep. Daarnaast krijgen de meeste 
pati­nten vandaag de dag ook chemotherapie en bestraling voor de operatie. 
Tijdens de operatie worden de tumor en een groot deel van de slokdarm 
verwijderd, om er zeker van te zijn dat de tumor in zijn geheel verwijderd is. 
Van de maag cre­ert de chirurg vervolgens een buis die als vervangende 
slokdarm dient. Deze buis wordt opgetrokken naar het stuk slokdarm wat na 
verwijdering nog over is en hieraan bevestigd.  Deze bevestiging heet een 
anastomose. De operatie voor slokdarmkanker is erg intensief en uitgebreid en 
het risico op complicaties na de operatie is niet gering. De herstelperiode is 
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lang en pati­nten hebben soms jaren na de operatie nog problemen met eten, 
misselijkheid, overgeven en zuurbranden. 
In dit proefschrift richten wij ons op chirurgische technieken die de overleving 
van slokdarmkankerpatiënten kunnen optimaliseren en kunnen voorkomen dat 
pati­nten lang na operatie nog problemen hebben. Ons doel is die technieken 
te vinden die de overlevingskans vergroten en de problemen verminderen, om 
deze pati­nten een positievere toekomst te geven. 
 
14.2 METHODEN 
Dit proefschrift is opgebouwd uit vijf studies.  
Voor deze studies hebben we drie verschillende bronnen van patiënten 
gebruikt. In studie I en II hebben we een grote, nationale, database gebruikt 
met uitgebreide informatie over pati­nten die verzameld is uit alle ziekenhuizen 
in Zweden die betrokken waren bij de behandeling van 
slokdarmkankerpati­nten tussen 1987 en 2010 (the Swedish Esophageal 
Cancer Surgery Study, or SESS). De onderzoekers uit onze groep hebben de 
data verzameld uit operatieverslagen, pati­ntendossiers en 
pathologieverslagen om zoveel mogelijk informatie te verzamelen over de 
pati­nten, de tumor en de behandeling.  
In studie III en IV hebben we een database gebruikt met pati­nten die 
geopereerd zijn voor slokdarm kanker tussen 2001 en 2005 in heel Zweden 
(the Swedish Esophageal and Cardia Cancer or SECC database). Het netwerk 
van chirurgen en andere medische specialisten die betrokken zijn bij de 
behandeling van en zorg voor slokdarmkanker pati­nte heeft de inzameling van 
deze data mogelijk gemaakt. Pati­nten werden direct nadat ze de diagnose 
gekregen hadden en deze bevestigd was door de patholoog in de database 
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opgenomen. In dit geval was het de patholoog die de pati­nten informatie 
doorstuurde aan onze projectcoördinator. Daarnaast werd de pati­nten 
gevraagd of ze een vragenlijst in wilde vullen over hun kwaliteit van leven en 
symptomen, dit werd op drie punten gedaan zes maanden, drie jaar en vijf jaar 
na hun operatie.   
In studie V is een database gebruikt die in het Erasmus MC Universitair 
Medisch Centrum (EMC) in Rotterdam is opgezet. Alle pati­nten vanaf 1978 en 
verder die behandeld zijn voor slokdarmkanker in het EMC  zijn opgenomen in 
de database. In studie V zijn alleen pati­nten inbegrepen die tussen 1990 en 
2010 zijn geopereerd. Informatie over de pati­nt, demografische gegevens, 
klinische data en details over de behandeling en de pathologie van de tumoren 
zijn uit de medische dossiers gehaald door een gespecialiseerd datamanager. 
In studie I is gekeken naar het aantal lymfeklieren dat tijdens een operatie 
wordt verwijderd (lymfeklier resectie) en hoe dat aantal de overleving van de 
pati­nt be±nvloedt. We hebben geprobeerd de vraag te beantwoorden of een 
uitgebreidere lymfeklier resectie de overleving verbetert in vergelijking met een 
minder uitgebreide lymfeklier resectie. 
In studie II hebben we gekeken naar de pati­nten die een heroperatie voor 
ernstige complicaties ondergingen binnen 30 dagen na de slokdarmkanker-
operatie. We vergeleken hierbij de invloed van de heroperatie op de overleving 
van pati­nten die opnieuw geopereerd zijn met die van pati­nten die niet 
opnieuw geopereerd zijn.  
In studie III hebben we geprobeerd een oplossing te vinden voor klachten van 
zuurbranden (reflux) na slokdarmoperatie door te kijken naar verschillende 
chirurgische ingrepen: 1) Een anastomose in de nek i.p.v. in de thorax, 2) een 
antireflux anastomose en 3) een snede in de maagportier (pyloromyotomy) wat 
het legen van de maag bevorderd.  
  93
In studie IV  is gekeken naar aanhoudende klachten en symptomen zes 
maanden na operatie voor slokdarmkanker in pati­nten die een lekkende 
anastomose hadden. We hebben de klachten en symptomen die deze 
pati­nten met een lekkende anastomose hadden, vergeleken met pati­nten die 
dit niet hebben doorgemaakt. 
In studie V hebben we gekeken naar het postoperatieve beloop van pati­nten 
met een gewichtsverlies van meer dan 10% in de drie maanden voor de 
vaststelling van de diagnose in vergelijking tot pati­nten met minder of geen 
gewichtsverlies. Er is gekeken naar de overlevingskans, het risico op 
postoperatieve complicaties en het aantal opnamedagen. 
In studie I, II en V is het risico op overlijden aan alle oorzaken, en het overlijden 
aan tumor recidief (terugkeer van de tumor) gedurende de vijf jaar na operatie 
berekend. Het risico op overlijden is berekend met een statistische methode 
“de Cox proportional hazard”. Het risico is berekend als hazard ratio (HR) met 
95% confidence interval (95% CI) en percentages (%).  
In studie III en IV zijn geselecteerde symptomen en klachten gemeten met 
behulp van een enqu¬te dat ontwikkeld is om symptomen en klachten te meten 
die veel voorkomen onder kankerpati­nten (EORTC QLQ-C30) en een module 
die symptomen meet die veel voorkomen onder slokdarmkankerpati­nten 
(EORTC QLQ-OES18). Deze enqu¬te en bijbehorende modules worden veel 
gebruikt in verschillende kankeronderzoek en geven een zeer betrouwbaar 
resultaat. Het risico op het ontwikkelen van symptomen (ja of nee) is berekend 
in de verschillende groepen. Het risico is berekend met een statistische 
methode, logistische regressie, en gepresenteerd als odds ratio (OR) met 95% 
confidence interval (95% CI). 
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14.3 RESULTATEN 
In de eerste studie zijn 1044 pati­nten opgenomen. De resultaten in studie I 
wezen er op dat een uitgebreidere lymfeklier resectie de overleving niet 
verbeterd. Huidige richtlijnen voor operatie adviseren een uitgebreidere 
lymfeklier resectie om de overleving te optimaliseren, ons onderzoek bevestigt 
dit niet. Wel zagen we dat pati­nten met meerdere lymfeklieren met 
uitzaaiingen een hoger risico op overlijden hadden van 274% (HR 2.74, 95% CI 
2.26-3.39) binnen vijf jaar. 
In studie II zijn 1481 patiënten opgenomen, die geopereerd zijn voor 
slokdarmkanker tussen 1987 en 2010. In totaal zijn 155 (11%) van deze 
pati­nten nogmaals geopereerd binnen 30 dagen na de eerste operatie omdat 
er ernstige complicaties optraden. Pati­nten die een heroperatie hebben 
ondergaan, hadden een 26% hoger risico op overlijden in de vijf jaar na 
operatie. Pati­nten die een lekkende anastomose hebben gehad, hadden een 
82% verhoogd risico op overlijden (HR 1.82 95% CI 1.19-2.76 
In studie III zijn 274 pati­nten opgenomen. Dertig (9.9%) hadden een 
anastomose in de hals, tweeënveertig (13.8%) hadden een antireflux 
anastomose en bij 184 (64%) was er tijdens de operatie een pyloromyotomy 
verricht. Het risico op reflux-symptomen was in geen van de drie groepen 
verlaagd. De reflux-symptomen waren vermeld door 23-29% van de pati­nten 
met een hals anastomose, antireflux anastomose of waarbij een 
pyloromyotomy is verricht.  
In studie IV hebben we 277 pati­nten opgenomen. Van deze patiënten hadden 
29 (10%) een lekkende anastomose in de borstkas. We zagen dat pati­nten 
met een lek een viervoudig verhoogd risico hadden op het ontwikkelen van eet 
problemen (OR 4.1, 95% CI 1.5.11.2) en een dubbel zo hoog risico op pijn 
tijdens het slikken (OR 2.6, 95% CI 1.1-5.8), gemeten zes maanden na de 
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operatie. De problemen met eten waren na drie jaar nog steeds aanwezig (OR 
2.0, 95% CI 1.0-32.4). 
Van de 922 patiënten in studie V had 155 (17%) meer dan 10% gewichtsverlies 
in de drie maanden voor de diagnose. We zagen dat pati­nten met meer dan 
10% gewichtsverlies geen verhoogd risico op postoperatieve complicaties 
hadden (OR 0.83, 95% CI 0.54-1.24) en geen langere opnameduur hadden 
dan pati­nten die geen of minder gewicht verloren hadden (HR 1.06, 95% CI 
0.85-1.33). Daarentegen hadden pati­nten met meer dan 10% gewichtsverlies 
wel een verhoogde kans op overlijden in de vijf jaar na operatie (HR, 1.34, 95% 
CI 102-1.74). 
 
14.4 CONCLUSIES  
Studie I: Een uitgebreidere lymfeklier resectie verbetert de overleving niet. Het 
is daarom misschien tijd om de geldende richtlijnen te herzien. Een hoger 
aantal lymfeklieren met uitzaaiingen verhoogde wel het risico op overlijden, 
zoals verwacht.  
Studie II: Pati­nten die na hun eerste operatie nogmaals geopereerd werden, 
hadden een verhoogde kans op overlijden van 27% in de eerste vijf jaar na 
operatie. Met name patiënten die nogmaals geopereerd zijn voor een lekkende 
anastomose hadden een verhoogd risico van 82%.  
Studie III: Een anastomose in de hals, een antireflux anastomose of 
pyloromyotomy beschermen niet tegen symptomen van reflux zes maanden na 
een operatie voor slokdarmkanker.  
Studie IV: Pati­nten die een lekkage van de anastomose hadden doorgemaakt, 
hebben een verhoogd risico op aanhoudende klachten van problemen met eten 
en pijn tijdens het slikken. 
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Studie V: Gewichtsverlies van meer dan 10% verhoogd het risico op overlijden 
in de eerste vijf jaar na een operatie, maar niet het risico op postoperatieve 
complicaties of een langere opnameduur.  
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